Therapeutic combinations of 4-1BB agonists and anti-CD20 antibodies
By combining CD19-targeted 4-1BBL antigen binding molecule with CD20 antibodies, the short half-life and toxicity of existing anti-CD20 antibody therapies are solved, and efficient treatment of B cell proliferative diseases is achieved, reducing the risk of treatment.
Patent Information
- Application Number
- CN202411106240.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-03-13
- Filing Date
- 2019-03-11
- Publication Date
- 2024-12-06
AI Technical Summary
Existing anti-CD20 antibody therapies such as bonatuzumab have severe cytokine release syndrome and central nervous system toxicity problems with short half-life, continuous pumping and high frequency in the treatment of B-cell proliferative conditions, and 4-1BB The safety and effectiveness of agonists still need to be improved.
Combining antigen-binding molecules containing three 4-1BBL exterodomains with specific antibodies, especially CD19-targeted 4-1BBL antigen-binding molecules with human CD20 antibodies (such as rituximab or obinotuzumab) Using, by specifically binding to CD19 and CD20 antigens, FcγR-mediated toxicity is reduced and the efficacy is improved.
This combination therapy is more effective than using anti-CD20 antibodies alone in inhibiting tumor growth and eliminating tumor cells, reducing the risk of cytokine release syndrome and central nervous system toxicity, and improving the safety and effectiveness of treating B-cell proliferative disorders. .
Smart Images

Figure BDA0004990900570000271 
Figure BDA0004990900570000281 
Figure BDA0004990900570000341
Abstract
Description
[0001] This application is a divisional application of an invention application filed on March 11, 2019, with Chinese application number 201980011952.4 and invention name “Therapeutic combination of 4-1BB agonist and anti-CD20 antibody”. Technical Field
[0002] The present invention relates to a combination therapy using a 4-1BB (CD137) agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, in particular a CD19-targeted 4-1BBL antigen binding molecule, and a specific antibody binding to human CD20, the use of these combination therapies for treating cancer, and methods of using the combination therapies. Background Art
[0003] B-cell proliferative disorders describe a heterogeneous group of malignancies, including both leukemias and lymphomas. Lymphomas arise from lymphocytes and include two major categories: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). In the United States, lymphomas of B-cell origin constitute approximately 80-85% of all non-Hodgkin's lymphoma cases, and there is considerable heterogeneity within B-cell subsets based on the genotype and phenotypic expression patterns in the B-cell of origin. For example, B-cell lymphoma subsets include slow-growing, indolent and incurable diseases such as follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL), as well as more aggressive subtypes, mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). Although a variety of agents for the treatment of B-cell proliferative disorders are available, there is a current need to develop safe and effective therapies to prolong regression and improve cure rates in patients.
[0004] One strategy currently under investigation is the engagement of T cells against malignant B cells. To effectively engage T cells against malignant B cells, two approaches have recently been developed. These two approaches are: 1) administration of T cells engineered ex vivo to recognize tumor cells (also known as chimeric antigen receptor-modified T cell therapy or CAR-T cells) (Maude et al., N Engl J Med (2014) 371, 1507-1517); and 2) administration of agents that activate endogenous T cells, such as bispecific antibodies (Oak and Bartlett, Expert Opin Investig Drugs (2015) 24, 715-724). An example of the first approach is reported in a study by Maude et al., in which 30 adult and pediatric patients were treated with autologous T cells (CTL019 CAR-T cells) transduced with a CD19-directed chimeric antigen receptor lentiviral vector. The result was sustained regression, based on a 67% 6-month event-free survival rate and an overall survival rate of 78%. However, all patients had cytokine release syndrome (CRS) (related to tumor burden), with 27% having severe CRS. A high frequency of central nervous system toxicity of unknown cause was also noted. A second approach involving activation of endogenous T cells to recognize tumor targets circumvents this scalability barrier and also offers competitive efficacy, safety data, and potential for long-term response duration. + In hematological malignancies, the best example of this approach is blinatumomab, a CD19 CD3-targeted T cell bispecific molecule (Bargou et al., Science (2008) 321, 974-977), which was recently approved for patients with minimal residual disease-positive acute lymphoblastic leukemia (ALL). This compound directs cytolytic T cells to lyse CD19 + cells. The main limitation of blinatumomab is its short half-life (approximately 2 hours), which necessitates continuous infusion via pump over 4-8 weeks. Furthermore, severe CRS and CNS toxicity have been observed frequently (Klinger et al., Blood (2012) 119(26), 6226-6233). Neurological toxicity occurred in approximately 50% of patients receiving blinatumomab in all clinical trials, and the types of toxicity observed are well defined in the package insert.
[0005] A member of the TNF receptor superfamily, 4-1BB (CD137) was originally identified as an inducible molecule expressed by T cell activation (Kwon and Weissman, Proc Natl Acad Sci USA (1989) 86, 1963-1967). Subsequent studies have shown that many other immune cells also express 4-1BB, including NK cells, B cells, NKT cells, monocytes, neutrophils, mast cells, dendritic cells (DC) and cells of non-hematopoietic origin such as endothelial and smooth muscle cells (Vinay and Kwon, Cell Mol Immunol. (2011) 8, 281-284). The expression of 4-1BB in different cell types is mostly induced and driven by various stimulatory signals, such as T cell receptor (TCR) or B cell receptor triggering, as well as signal transduction induced by receptors of co-stimulatory molecules or proinflammatory cytokines (Diehl et al., J Immunol (2002) 168, 3755-3762; Zhang et al., J Immunol (2010) 184, 787-795).
[0006] 4-1BB ligand (4-1BBL or CD137L) was identified in 1993 (Goodwin et al., Eur J Immunol. (1993) 23, 2631-2641). It has been shown that the expression of 4-1BBL is restricted on professional antigen presenting cells (APCs) such as B cells, DCs and macrophages. The inducible expression of 4-1BBL is characteristic for T cells including both αβ and γδ T cell subsets, and endothelial cells (Shao and Schwarz, J Leukoc Biol (2011) 89, 21-29).
[0007] Activation of T cells (CD4 + and CD8 +The 4-1BB-specific antibody can enhance T cell proliferation, stimulate lymphokine secretion and reduce the sensitivity of T lymphocytes to activation-induced cell death (Snell et al., Immunol Rev (2011) 244, 197-217). This mechanism has been further developed as the first proof of concept in cancer immunotherapy. In a preclinical model, the administration of agonist antibodies against 4-1BB in tumor-bearing mice resulted in a powerful anti-tumor effect (Melero et al., Nature Med (1997) 3, 682-685). Subsequently, increasing evidence indicated that 4-1BB generally exhibits its efficacy as an anti-tumor agent only when administered in combination with other immunomodulatory compounds, chemotherapeutic agents, tumor-specific vaccination or radiotherapy (Bartkowiak and Curran, Front Oncol (2015) 5, 117).
[0008] Signaling by the TNFR superfamily requires cross-linking of trimeric ligands to engage the receptor, and thus requires wild-type Fc-bound 4-1BB agonistic antibodies (Li and Ravetch, Science (2011) 333, 1030-1034). However, in mice, systemic administration of 4-1BB-specific agonistic antibodies with a functionally active Fc domain resulted in CD8+-associated hepatotoxicity. + T cell influx (Dubrot et al., Cancer Immunol Immunother (2010) 59, 1223-1233), which is attenuated or significantly reduced in the absence of functional Fc receptors. In the clinic, an Fc-competent 4-1BB agonist antibody (BMS-663513) (NCT00612664) caused grade 4 hepatitis, leading to trial termination (Simeone and Ascierto, J Immunotoxicol (2012) 9, 241-247). Therefore, effective and safer 4-1BB agonists are needed.
[0009] Fusion proteins consisting of an extracellular domain of a 4-1BB ligand and a single-chain antibody fragment (Hornig et al., J Immunother (2012) 35, 418-429; Müller et al., J Immunother. (2008) 31, 714-722) or a single 4-1BB ligand fused to the C-terminus of the heavy chain (Zhang et al., Clin Cancer Res (2007) 13, 2758-2767) have been generated. WO 2010 / 010051 discloses the generation of a fusion protein consisting of three TNF ligand extracellular domains connected to each other and fused to an antibody portion. In the present invention, an antigen binding molecule consisting of a trimerized and thus biologically active 4-1BB ligand and an antigen binding domain specific to a tumor antigen CD19 and an Fc region lacking FcγR binding is shown to be particularly stable and robust (referred to herein as CD19-4-1BBL). These constructs are disclosed in WO 2016 / 075278 and replace non-specific FcγR-mediated cross-linking responsible for Fc-mediated toxicity with CD19-targeted B cell-specific cross-linking.
[0010] CD19 is an ideal target for immunotherapy of B cell malignancies because it is expressed on the surface of B cells and is almost specific to these cells. CD19 is more widely expressed on B cells than CD20 during B cell development, so typically CD20-positive cells will also express CD19. During B cell differentiation toward plasma cells (antibody-secreting cells), B cells downregulate CD20 expression. Sometimes, B cell lymphomas also downregulate CD20 expression, but remain positive for CD19. Therefore, targeting both CD19 and CD20 will provide broad coverage of diseased B cells in lymphomas, which may also shift the selection pressure from CD20 to both CD19 and CD20. Although it is not known whether CD19 contributes directly to B cell carcinogenesis, its expression is highly conserved on most B cell tumors, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B cell lymphomas. In acute leukemias, CD19 is stably and continuously expressed on almost all subtypes while only a few leukemias express CD20.
[0011] There remains a need for novel compounds and combinations that are likely to make a significant contribution to the treatment of patients with B cell proliferative disorders, such as NHL and CLL. It has been found that superior anti-tumor effects are achieved when a CD19-targeting 4-1BBL antigen binding molecule is combined with a specific antibody that binds to human CD20. Thus, we describe herein a novel combination therapy for cancers with B cell malignancies. Summary of the invention
[0012] The present invention relates to a 4-1BB (CD137) agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly an antigen binding molecule comprising three 4-1BBL outer domains, and its use in a method for treating cancer or delaying cancer progression, more particularly for treating B cell proliferative disorders or delaying B cell proliferative disorder progression, in combination with antibodies binding to human CD20, particularly rituximab or obinutuzumab. It has been found that the combination therapy described herein is more effective than treatment with anti-CD20 antibodies alone in inhibiting tumor growth and eliminating tumor cells.
[0013] In one aspect, the present invention provides a 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, in particular the 4-1BB agonist comprises three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.
[0014] In particular, the 4-1BB agonist is an antigen binding molecule comprising an antigen binding domain capable of specifically binding to CD19. In one aspect, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain. In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising a modified Fc domain that reduces or preferably eliminates Fcγ receptor binding and / or effector function.
[0015] In one aspect, the 4-1BB agonist and the anti-CD20 antibody are administered concomitantly or simultaneously. In another aspect, a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression is provided, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
[0016] In one aspect, the present invention provides a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist comprises three 4-1BBL outer domains or fragments thereof. In another aspect, a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression is provided, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL outer domains or fragments thereof and wherein the 4-1BBL outer domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular, an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5. More particularly, the 4-1BBL outer domain comprises an amino acid sequence of SEQ ID NO: 5.
[0017] In one aspect, the present invention provides a 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to CD19.
[0018] In one aspect, the antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL outer domains or fragments thereof will not be internalized by CD19-expressing B cells. In another aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL outer domains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V H CD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V LCD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V H CD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L CD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0019] In a specific aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL external domains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V L ... H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L In one particular aspect, the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0020] In one aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably combining. In particular, the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function. In a specific aspect, the 4-1BB agonist comprises an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0021] In another aspect of the present invention, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0022] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0023] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0024] wherein the first polypeptide comprises two 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker and wherein the second polypeptide comprises one 4-1BBL ectodomain or fragment thereof.
[0025] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0026] (a) at least one Fab domain capable of specifically binding to CD19, and
[0027] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0028] wherein the antigen binding molecule is characterized by
[0029] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0030] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0031] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof connected to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof connected to the VL or VH of said polypeptide via a peptide linker.
[0032] In one aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0033] (a) at least one Fab domain capable of specifically binding to CD19, the Fab domain capable of specifically binding to CD19 comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19), and
[0034] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0035] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0036] In one specific aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0037] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0038] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0039] c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:39, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:40;
[0040] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:33, a first light chain comprising the amino acid sequence of SEQ ID NO:34, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41, and a second light chain comprising the amino acid sequence of SEQ ID NO:42;
[0041] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0042] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0043] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0044] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0045] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 48, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 49, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 50;
[0046] j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 47, a first light chain comprising the amino acid sequence of SEQ ID NO: 48, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0047] k) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and
[0048] l) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:48, a first heavy chain comprising the amino acid sequence of SEQ ID NO:51 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:52.
[0049] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0050] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0051] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0052] In one specific aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0053] (a) A molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53,
[0054] (b) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19) and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53;
[0055] (c) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 54, and
[0056] (d) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (VL CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO:55.
[0057] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an anti-CD19 / anti-4-1BB bispecific antibody.
[0058] In yet another aspect, the present invention provides a 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to FAP.
[0059] In one aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to FAP and three 4-1BBL external domains or fragments thereof, wherein the antigen binding domain capable of specifically binding to FAP comprises
[0060] (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 96, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 97, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 98, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 99, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 100, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 101, or
[0061] (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 102, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 103, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 104, the light chain variable region (V LFAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:105, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:106, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:107.
[0062] In a specific aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to FAP and three 4-1BBL external domains or fragments thereof, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V L ... H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 111 L In one particular aspect, the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).
[0063] In one aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to FAP is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably combining. In particular, the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function. In a specific aspect, the 4-1BB agonist comprises an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0064] In another aspect of the present invention, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0065] (a) at least one antigen binding domain capable of specifically binding to FAP,
[0066] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0067] wherein the first polypeptide comprises two 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker and wherein the second polypeptide comprises one 4-1BBL ectodomain or fragment thereof.
[0068] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0069] (a) at least one Fab domain capable of specifically binding to FAP, and
[0070] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0071] wherein the antigen binding molecule is characterized by
[0072] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0073] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0074] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof connected to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof connected to the VL or VH of said polypeptide via a peptide linker.
[0075] In one aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0076] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 110 H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 111 L FAP), and
[0077] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0078] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0079] In one specific aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0080] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 112, a first light chain comprising the amino acid sequence of SEQ ID NO: 113, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0081] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 112, a first light chain comprising the amino acid sequence of SEQ ID NO: 113, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0082] c) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 112, a first light chain comprising the amino acid sequence of SEQ ID NO: 113, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0083] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 112, a first light chain comprising the amino acid sequence of SEQ ID NO: 113, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0084] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 114, a first light chain comprising the amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0085] f) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 114, a first light chain comprising the amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0086] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 114, a first light chain comprising the amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0087] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 114, a first light chain comprising the amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0088] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0089] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0090] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0091] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 113, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 116, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 117; and
[0092] j) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:115, a first heavy chain comprising the amino acid sequence of SEQ ID NO:118 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:119.
[0093] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0094] (a) at least one antigen binding domain capable of specifically binding to FAP,
[0095] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0096] In another aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.
[0097] In all these aspects, the present invention further provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the anti-CD20 antibody comprises a type I anti-CD20 antibody. In particular, the anti-CD20 antibody is rituximab. In another aspect, the present invention further provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the anti-CD20 antibody is a type II anti-CD20 antibody. In particular, the anti-CD20 antibody is obinutuzumab. In one aspect, the anti-CD20 antibody is an afucosylated anti-CD20 antibody. In yet another aspect, the anti-CD20 antibody is rituximab or obinutuzumab.
[0098] In another aspect, provided is a 4-1BB agonist as previously defined herein for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and wherein the combination is administered at intervals of about one to three weeks.
[0099] In another aspect, provided is a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression in combination with an anti-CD20 antibody, wherein the 4-1BB agonist is a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and wherein pretreatment with a type II anti-CD20 antibody, preferably utuzumab, is performed prior to the combined treatment, wherein the time period between the pretreatment and the combined treatment is sufficient to reduce B cells in the individual in response to the type II anti-CD20 antibody, preferably utuzumab.
[0100] In yet another aspect, the present invention provides a pharmaceutical product comprising (A) a first composition comprising as an active ingredient a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a pharmaceutically acceptable excipient; and (B) a second composition comprising as an active ingredient an anti-CD20 antibody and a pharmaceutically acceptable excipient, for use in combined or simultaneous treatment of a disease, particularly cancer.
[0101] In another aspect, a pharmaceutical composition is provided, comprising a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and a pharmaceutically acceptable excipient, and a second drug comprising an anti-CD20 antibody. In one aspect, the pharmaceutical composition is for use as a medicament. In particular, the pharmaceutical composition is for use in the treatment of B cell proliferative disorders, particularly selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin lymphoma (HL).
[0102] In another aspect, the present invention provides a kit for treating cancer or delaying cancer progression in a subject, comprising a package comprising (A) a first composition comprising as an active ingredient a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a pharmaceutically acceptable excipient; (B) a second composition comprising as an active ingredient an anti-CD20 antibody and a pharmaceutically acceptable excipient; and (C) instructions for use of the composition in combination therapy.
[0103] In yet another aspect, the present invention relates to the use of a combination of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and an anti-CD20 antibody in the manufacture of a medicament for treating a proliferative disease, particularly cancer, or delaying the progression of a proliferative disease, particularly cancer.
[0104] In particular, provided is the use of a combination of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and an anti-CD20 antibody in the manufacture of a medicament for treating a disease selected from the group consisting of non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin's lymphoma (HL).
[0105] In another aspect, the present invention provides a method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and an effective amount of an anti-CD20 antibody. In particular, the present invention relates to a method for treating cancer or delaying cancer progression in a subject, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP. In one aspect, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain. In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising a modified Fc domain that reduces Fcγ receptor binding and / or effector function. In a specific aspect, the 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof. More specifically, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and an antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP.
[0106] In another aspect, the present invention provides a method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and an effective amount of an anti-CD20 antibody, wherein the 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions. In particular, the 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and the anti-CD20 antibody are administered intravenously or subcutaneously. In another aspect, the 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, is administered concomitantly with the anti-CD20 antibody. BRIEF DESCRIPTION OF THE DRAWINGS
[0107] Figure 1Specific CD19-4-1BBL antigen binding molecules used in the examples are shown. These molecules are described in more detail in Examples 1 and 2, respectively. Dark black dots represent knob-into-hole modifications. (1A) shows a monovalent CD19 antigen binding molecule containing a 4-1BBL trimer with amino acid modifications in the CH1 and CL domains adjacent to the 4-1BBL dimer and 4-1BBL monomer. Because it contains the CD19 binder 8B8-018, it is named mono CD19(018)-4-1BBL herein. The construct shown in (1B) differs from (1A) in that it contains the CD19 binder 8B8-2B11 and is therefore called mono CD19(2B11)-4-1BBL. (1D) shows a bivalent construct with the binder CD19(018), called bi CD19(018)-4-1BBL. (1C) and (1E) show non-targeting control molecules (the CD19 binder has been replaced with a non-binding DP47 Fab). (1F) shows a monovalent CD19 4-1BBL-trimer-containing antigen binding molecule comprising a murine 4-1BBL dimer and a murine 4-1BBL monomer, referred to herein as hybrid CD19-4-1BBL or CD19-mu4-1BBL.
[0108] exist Figure 2 In (2A), the setting of the assay for measuring the simultaneous binding of CD19-targeted trimer split 4-1BBL to mouse 4-1BB and human CD19 (Example 2) is shown. The figure in (2B) shows the simultaneous binding of the hybrid surrogate CD19-mu4-1BBL (analyte 1) to immobilized mouse 4-1BB and human CD19 (analyte 2).
[0109] exist Figure 3 In (3A) to (3C), the results are shown in the case of an interfering NHL cell line, WSU-DLCL2 (CD19 + CD20 高 )((3A)),SU-DHL-8(CD19 + CD20 低 )((3B)), or Naml-6(CD19 + CD20 低 )((3C)) CD19-4-1BBL can enhance the activation of NK cells (IFNγ release) activated by rituximab or obinutuzumab (Gazyva).
[0110] exist Figure 4 In (4A) to (4C), we show that in the intergenic NHL cell line, WSU-DLCL2 (CD19 + CD20 高 )((4A)),SU-DHL-8(CD19+ CD20 低 )((4B)), or Naml-6(CD19 + CD20 低 ) ((4C)) NK cell activation (CD25 upregulation) was enhanced by combining CD19-4-1BBL with rituximab or obinutuzumab (Gazyva).
[0111] exist Figure 5 5A to (5C) show that the combination of CD19-4-1BBL and obinutuzumab (Gazyva) enhanced NK cell activation (CD25 upregulation) when entrained to the NHL cell lines WSU-DLCL2 ((5A)), SU-DHL-8 ((5B)), or Naml-6 ((5C)), while the combination of usulelumab and obinutuzumab did not.
[0112] Figure 6 The scheme of the in vivo efficacy study of the monovalent hybrid CD19-4-1BBL molecule (mono CD19-mu4-1BBL) in combination with rituximab in huCD16Tg Scid mice is shown. The mouse subgroups receiving different combinations and dosages are defined in the table below. The experiment is described in Example 4 and the results are shown in (7A) and (7B). The combination of mono CD19-mu4-1BBL and rituximab does induce stronger and faster tumor growth inhibition than the monotherapy of rituximab or the monotherapy of mono CD19-mu4-1BBL in all doses tested. As shown in (7B), the tumor weight at the time of study termination confirmed these findings.
[0113] Figure 8 The protocol for in vivo efficacy study of monovalent CD19(2B11)-4-1BBL constructs in combination with Obinutuzumab (Gazyva) in fully humanized NSG mice bearing WSU-DLCL2 is shown. The subsets of mice receiving different combinations and doses are defined in the table below. The experiments are described in Example 5 and in Fig. 9 The results are shown in. The combination of mono CD19(2B11)-4-1BBL and Gazyva induced much stronger tumor growth inhibition compared to Gazyva monotherapy. DETAILED DESCRIPTION
[0114] definition
[0115] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs. For the purpose of interpreting this specification, the following definitions will apply and, where appropriate, terms used in the singular will also include the plural and vice versa.
[0116] As used herein, the term "antigen binding molecule" refers in its broadest sense to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments, and scaffold antigen binding proteins.
[0117] The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0118] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible antibody variants, e.g., containing naturally occurring mutations or generated during the generation of a monoclonal antibody preparation, such variants generally being present in minute amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen.
[0119] The term "monospecific" antibody as used herein refers to an antibody having one or more binding sites, each of which binds to the same epitope of the same antigen. The term "bispecific" means that the antigen binding molecule is capable of specifically binding to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant. In certain embodiments, a bispecific antigen binding molecule is capable of simultaneously binding to two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.
[0120] The term "valency" as used in this application refers to the presence of a specified number of binding sites in an antigen binding molecule. As such, the terms "divalent", "tetravalent", and "hexavalent" refer to the presence of two binding sites, four binding sites, and six binding sites in an antigen binding molecule, respectively. "Monovalent" refers to the presence of only one binding domain for a specific target in an antigen binding molecule.
[0121] The terms "full-length antibody", "intact antibody", and "whole antibody" are used interchangeably herein to refer to antibodies having a structure substantially similar to that of a natural antibody. "Native antibody" refers to naturally occurring immunoglobulin molecules with different structures. For example, natural IgG class antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, consisting of two light chains and two heavy chains that are disulfide bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chains of antibodies can be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which can be further divided into subtypes, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of antibodies can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domains.
[0122] "Antibody fragment" refers to a molecule that is different from an intact antibody and that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies, triabodies, tetrabodies, crossover Fab fragments; linear antibodies; single-chain antibody molecules (e.g., scFv); and single-domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments containing salvage receptor binding epitope residues and having extended in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments having two antigen binding sites that can be bivalent or bispecific, see, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single domain antibodies are antibody fragments that contain all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, the single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516B1). Antibody fragments can be generated by various techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phage), as described herein.
[0123] Papain digestion of intact antibodies generates two identical antigen-binding fragments, called "Fab" fragments, each containing the variable domains of the heavy and light chains, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Thus, as used herein, the term "Fab fragment" refers to an antibody fragment comprising a light chain fragment comprising the VL domain and the constant domain (CL) of the light chain, and the VH domain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the CH1 domain of the heavy chain, including one or more cysteines from the hinge region of the antibody. Fab'-SH is a Fab' fragment in which the cysteine residues of the constant domains carry free thiol groups. Pepsin treatment produces a F(ab')2 fragment with two antigen-binding sites (two Fab fragments) and a portion of the Fc region.
[0124] The term "crossover Fab fragment" or "xFab fragment" or "exchange Fab fragment" refers to a Fab fragment in which either the variable region or the constant region of the heavy and light chain is exchanged. Two different chain compositions of the exchange Fab molecule are possible and are included in the bispecific antibodies of the present invention: on the one hand, the variable regions of the Fab heavy and light chains are exchanged, that is, the exchange Fab molecule comprises a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1), and a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL). Such an exchange Fab molecule is also called CrossFab (VLVH) On the other hand, when the constant regions of the heavy and light chains of Fab are exchanged, the exchange Fab molecule contains a peptide chain consisting of the heavy chain variable region (VH) and the light chain constant region (CL), and a peptide chain consisting of the light chain variable region (VL) and the heavy chain constant region (CH1). This exchange Fab molecule is also called CrossFab. (CLCH1) .
[0125] "Single-chain Fab fragments" or "scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL; and wherein the linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single-chain Fab fragments are stabilized via natural disulfide bonds between the CL domain and the CH1 domain. In addition, these single-chain Fab molecules can be further stabilized by generating interchain disulfide bonds via the insertion of cysteine residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).
[0126] "Exchange single-chain Fab fragments" or "x-scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL together form an antigen binding site that specifically binds to an antigen, and wherein the linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules can be further stabilized by generating interchain disulfide bonds through the insertion of cysteine residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).
[0127] A "single-chain variable fragment (scFv)" is a heavy chain variable fragment of an antibody joined to a short linker peptide of 10 to about 25 amino acids. H ) and light (V L ) chain variable region fusion protein. The linker is often rich in glycine for flexibility, and serine or threonine for solubility, and V H The N-terminal and V L The antibody fragment is a fragment of a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a fragment of a VH domain that is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention. The polypeptide is a polypeptide that is a polypeptide of the invention.
[0128] "Scaffold antigen binding protein" is known in the art, for example, fibronectin and designed ankyrin repeat protein (DARPin) have been used as alternative scaffolds for antigen binding domains, see, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13: 245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008). In one aspect of the present invention, the scaffold antigen binding protein is selected from CTLA-4 (Evibody), lipocalin (Anticalin), protein A derived molecules, such as protein A Z domain (Affibody), A domain (Avimer / Maxibody), serum transferrin (trans-body); designed ankyrin repeat protein (DARPin), variable domain of antibody light chain or heavy chain (single domain antibody, sdAb), variable domain of antibody heavy chain (nanobody, aVH), V NAR fragment, fibronectin (AdNectin), C-type lectin domain (Tetranectin); novel antigen receptor β-lactamase variable domain (V NAR fragments), human γ-crystallin or ubiquitin (Affilin molecules); Kunitz-type domains of human protease inhibitors, microbodies, such as proteins from the knottin family, peptide aptamers and a group consisting of fibronectin (adnectin).
[0129] Lipocalins are a family of extracellular proteins that transport small hydrophobic molecules such as steroids, bilirubin, retinoids and lipids. They have a rigid β-sheet secondary structure with loops at the open end of the cone structure that can be engineered to bind different target antigens. Anticalins range in size from 160-180 amino acids and are derived from lipocalins. For further details, see Biochim Biophys Acta 1482:337-350 (2000), US7250297B1 and US20070224633.
[0130] Designed ankyrin repeat proteins (DARPins) are derived from ankyrin, a family of proteins that mediate the attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33-residue motif consisting of two α-helices and a β-turn. By randomizing the residues in the first α-helix and β-turn of each repeat, they can be engineered to bind different target antigens. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details, see J. Mol. Biol. 332, 489-503 (2003), PNAS 100 (4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1.
[0131] Single domain antibodies are antibody fragments consisting of a single monomeric variable antibody domain. The first single domains are derived from the variable domains of antibody heavy chains from camelids (nanobodies or V H H fragment). Furthermore, the term single domain antibody includes autonomous human heavy chain variable domains (aVH) or VH derived from sharks. NAR Fragment.
[0132] An "antigen-binding molecule that binds to the same epitope as a reference molecule" refers to an antigen-binding molecule that blocks the binding of the reference molecule to its antigen by 50% or more in a competition assay, whereas the reference molecule blocks the binding of the antigen-binding molecule to its antigen by 50% or more in a competition assay.
[0133] The term "antigen binding domain" refers to the portion of an antigen binding molecule that contains a region that specifically binds to and is complementary to part or all of an antigen. In the case of a large antigen, an antigen binding molecule may only bind to a specific portion of the antigen, which is called an epitope. The antigen binding domain can be provided by, for example, one or more variable domains (also referred to as variable regions). Preferably, the antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
[0134] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to the following site on the polypeptide macromolecule (e.g., a continuous segment of amino acids or a conformational structure composed of different regions of discontinuous amino acids), to which the antigen binding module binds to form an antigen binding module-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or in the extracellular matrix (ECM). Proteins useful as antigens herein can be any natural form of proteins from any vertebrate source, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise specified. In a specific embodiment, the antigen is a human protein. In the case of referring to a specific protein herein, the term encompasses "full-length" unprocessed proteins as well as any form of proteins derived from processing in cells. The term also encompasses naturally occurring variants of proteins, such as splice variants or allelic variants.
[0135] "Specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen-binding molecule to bind a specific antigen can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of the antigen-binding molecule to an unrelated protein is less than about 10% of the binding of the antigen-binding molecule to the antigen, as measured by, for example, SPR. In certain embodiments, the antigen-binding molecule has a specific binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or smaller, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 The dissociation constant (Kd) of the
[0136] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd), which is the dissociation and association rate constants (k, respectively). off and k on Thus, equivalent affinities may comprise different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. One particular method for measuring affinity is surface plasmon resonance (SPR).
[0137] As used herein, "B cell antigen" refers to an antigenic determinant presented on the surface of B lymphocytes, particularly malignant B lymphocytes (in which case the antigen is also referred to as a "malignant B cell antigen").
[0138] The term "tumor-associated antigen" means any antigen that is highly expressed by tumor cells or in the tumor stroma. Specific tumor-associated antigens are CD19 or FAP.
[0139] The term "CD19" refers to the B lymphocyte antigen CD19, also known as the B lymphocyte surface antigen B4 or the T cell surface antigen Leu-12, and includes any native CD19 of any vertebrate origin, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise specified. The amino acid sequence of human CD19 is shown in Uniprot Accession No. P15391 (version 160, SEQ ID NO: 62). The term encompasses "full-length", unprocessed human CD19 as well as any form of human CD19 derived from processing in cells, as long as the antibodies reported herein bind to it. CD19 is a structurally unique cell surface receptor expressed on the surface of human B cells, including but not limited to pre-B cells, B cells in early development (i.e., immature B cells), mature B cells through terminal differentiation into plasma cells, and malignant B cells. CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B-cell chronic lymphocytic leukemias (CLL), prolymphocytic leukemias, hairy cell leukemias, common acute lymphoblastic leukemias, and some Null-acute lymphoblastic leukemias. CD19 expression on plasma cells further suggests that it may be expressed on differentiated B-cell tumors such as multiple myeloma. Therefore, the CD19 antigen is a target for immunotherapy for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.
[0140] The term "CD20" refers to the B lymphocyte antigen CD20, also known as the B lymphocyte surface antigen B1 or the leukocyte surface antigen Leu-16, and includes any native CD20 from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise indicated. The amino acid sequence of human CD20 is shown in Uniprot accession number P11836 (version 149, SEQ ID NO: 63). CD20 is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD, expressed on pre-B and mature B lymphocytes. The corresponding human gene is transmembrane 4 domains, subfamily A, member 1, also known as MS4A1. This gene encodes a member of the transmembrane 4A gene family. Members of this new protein family are characterized by common structural features and similar intron / exon splicing boundaries and display unique expression patterns between hematopoietic cells and non-lymphoid tissues. This gene encodes a B lymphocyte surface molecule that plays a role in B cell development and differentiation into plasma cells. This family member is located at 11q12 among a cluster of family members. Alternative splicing of this gene produces two transcript variants encoding the same protein. The term "CD20" encompasses "full-length," unprocessed CD20 as well as any form of CD20 that results from processing in the cell. The term also encompasses naturally occurring variants of CD20, such as splice variants or allelic variants.
[0141] The terms "anti-CD20 antibody" and "antibody that binds to CD20" refer to an antibody that is capable of binding to CD20 with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent in targeting CD20. In one embodiment, the extent of binding of the anti-CD20 antibody to an unrelated, non-CD20 protein is less than about 10% of the binding of the antibody to CD20, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the antibody that binds to CD20 has a binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 In certain embodiments, the anti-CD20 antibody binds to a CD20 epitope that is conserved among CD20 from different species.
[0142] "Type II anti-CD20 antibody" means an anti-CD20 antibody having the binding properties and biological activity of a Type II anti-CD20 antibody described in Cragg et al., Blood 103 (2004) 2738-2743; Cragg et al., Blood 101 (2003) 1045-1052; Klein et al., mAbs 5 (2013), 22-33, and summarized in Table 1 below.
[0143] Table A: Characteristics of Type I and Type II anti-CD20 antibodies
[0144] Type I Anti-CD20 Antibodies Type II anti-CD20 antibodies Binds to class I CD20 epitope Binds to class II CD20 epitope Localization of CD20 to lipid rafts CD20 does not localize to lipid rafts High CDC* Low CDC* ADCC activity* ADCC activity* Complete B cell binding capacity About half of the ability to bind to B cells Weak homotypic aggregation Homotypic aggregation Low cell death induction Strong cell death induction
[0145] *If IgG1 isotype
[0146] Examples of type II anti-CD20 antibodies include, e.g., obinutuzumab (GA101), tositumumab (B1), humanized B-Ly1 antibody IgG1 (a chimeric humanized IgG1 antibody, as disclosed in WO 2005 / 044859), 11B8 IgG1 (as disclosed in WO 2004 / 035607) and AT80 IgG1.
[0147] In one aspect, the type II anti-CD20 antibody comprises a heavy chain variable region sequence (V H) comprising HCDR1 of SEQ ID NO: 73, HCDR2 of SEQ ID NO: 74, and HCDR3 of SEQ ID NO: 75. H CD20) and a light chain variable region sequence comprising LCDR1 of SEQ ID NO:76, LCDR2 of SEQ ID NO:77, and LCDR3 of SEQ ID NO:78 (V L CD20). In another aspect, the type II anti-CD20 antibody is engineered to have an increased proportion of non-fucosylated oligosaccharides in the Fc region compared to the unengineered antibody. In one aspect, at least about 40% of the N-linked oligosaccharides in the Fc region of the type II anti-CD20 antibody are non-fucosylated.
[0148] In a specific aspect, the type II anti-CD20 antibody is obinutuzumab (recommended INN, WHO drug information, Vol. 26, No. 4, 2012, p. 453). As used herein, obinutuzumab is synonymous with GA101. The trade name is or This replaces all previous forms (e.g. Vol. 25, No. 1, 2011, p. 75-76), and was previously known as afutuzumab (Recommended INN, WHO Drug Information, Vol. 23, No. 2, 2009, p. 176; Vol. 22, No. 2, 2008, p. 124). In one embodiment, the type II anti-CD20 antibody comprises a heavy chain variable region sequence of SEQ ID NO: 79 and a light chain variable region sequence of SEQ ID NO: 80. In one aspect, the type II anti-CD20 antibody is tositumomab.
[0149] "Type I anti-CD20 antibody" means an anti-CD20 antibody selected from the group consisting of rituximab, ofatumumab, veltuzumab, ocaratuzumab, ocrelizumab, PRO131921, ublituximab, HI47 IgG3 (ECACC, hybridoma), 2C6 IgG1 (as disclosed in WO 2005 / 103081), 2F2 IgG1 (as disclosed in WO 2004 / 035607 and WO 2005 / 103081) and 2H7 IgG1 (as disclosed in WO2004 / 056312). A specific type I anti-CD20 antibody is rituximab.
[0150] "Rituximab" is a genetically engineered chimeric monoclonal antibody against the human CD20 antigen containing a human gamma 1 murine constant domain. This chimeric antibody contains a human gamma 1 constant domain and is identified by the name "C2B8" in US 5,736,137 (Andersen et al.), issued on April 17, 1998, assigned to IDEC Pharmaceuticals Corporation. Rituximab is approved for the treatment of patients with relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma. In vitro mechanism of action studies have shown that rituximab exhibits human complement-mediated cytotoxicity (CDC) (Reff, ME et.al., Blood 83 (1994) 435-445). In addition, it exhibits significant activity in an assay measuring antibody-dependent cellular cytotoxicity (ADCC). Rituximab is not afucosylated.
[0151] The term "humanized B-Ly1 antibody" refers to humanized B-Ly1 antibodies as disclosed in WO 2005 / 044859 and WO 2007 / 031875, which are obtained from the murine monoclonal anti-CD20 antibody B-Ly1 (murine heavy chain variable region (VH): SEQ ID NO: 64; murine light chain variable region (VL): SEQ ID NO: 65 (see Poppema, S. and Visser, L., Biotest Bulletin 3 (1987) 131-139) by chimerization with human constant domains from IgG1 and subsequent humanization (see WO 2005 / 044859 and WO 2007 / 031875). These "humanized B-Ly1 antibodies" are disclosed in detail in WO 2005 / 044859 and WO 2007 / 031875.
[0152] The term "fibroblast activation protein (FAP)", also known as prolyl endopeptidase FAP or seprase (EC 3.4.21), refers to any native FAP from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term includes "full-length" unprocessed FAP as well as any form of FAP derived from processing in cells. The term also encompasses naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen binding molecules of the present invention are capable of specifically binding to human, mouse and / or cynomolgus monkey FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) accession number Q12884 (version 149, SEQ ID NO: 120), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to 760. The amino acid sequence of human FAP ECD with a His tag is shown in SEQ ID NO: 121. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321 (version 126, SEQ ID NO: 122), or NCBI RefSeq NP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to 761. SEQ ID NO: 123 shows the amino acid sequence of mouse FAP ECD with a His tag. SEQ ID NO: 124 shows the amino acid sequence of cynomolgus monkey FAP ECD with a His tag. Preferably, the anti-FAP binding molecules of the present invention bind to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in International Patent Application No. WO 2012 / 020006 A2.
[0153] The term "reduced" (and its grammatical variations, such as "reduced" or "reduced"), e.g. a decrease in the number of B cells or cytokine release, refers to a decrease in the corresponding quantity measured by a suitable method known in the art. For the sake of clarity, the term also includes a decrease to zero (or below the detection limit of the analytical method), i.e. a complete elimination or elimination. In contrast, "increase" refers to an increase in the corresponding quantity.
[0154] As used herein, "T cell antigen" refers to an antigenic determinant presented on the surface of T lymphocytes, particularly cytotoxic T lymphocytes.
[0155] As used herein, "T cell activating therapeutic agent" refers to a therapeutic agent capable of inducing T cell activation in a subject, particularly a therapeutic agent designed to induce T cell activation in a subject. Examples of T cell activating therapeutic agents include bispecific antibodies that specifically bind to activating T cell antigens, such as CD3, and target cell antigens, such as CD20 or CD19. Other examples include chimeric antigen receptors (CARs) comprising a T cell activating domain and an antigen binding module that specifically binds to a target cell antigen, such as CD20 or CD19.
[0156] As used herein, "activating T cell antigen" refers to an antigenic determinant expressed by T lymphocytes, particularly cytotoxic T lymphocytes, which can induce or enhance T cell activation after interaction with an antigen binding molecule. In particular, the interaction of an antigen binding molecule with an activating T cell antigen can induce T cell activation, which is carried out by triggering the signal transduction cascade of the T cell receptor complex. An exemplary activating T cell antigen is CD3.
[0157] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in the binding of an antigen-binding molecule to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity.
[0158] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence and / or forms a structurally defined loop ("hypervariable loop"). Typically, a natural four-chain antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). HVRs generally comprise amino acid residues from hypervariable loops and / or from "complementarity determining regions" (CDRs), the latter of which have the highest sequence variability and / or are involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987)). Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35B (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)).
[0159] Hypervariable regions (HVRs) are also referred to as complementarity determining regions (CDRs), and these terms are used interchangeably herein when referring to the portion of the variable region that forms the antigen binding region. This particular region has been described by Kabat et al., U. S. Pat. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and by Chothia et al., J. Mol. Biol. 196: 901-917 (1987), wherein the definition includes an overlap or subset of amino acid residues when compared to each other. In any case, the application of any definition to refer to the CDR of an antibody or its variants is intended to be within the scope of the term as defined and used herein. Suitable amino acid residues covering the CDRs defined by each of the references cited above are listed as a comparison in Table B below. The exact residue number covering a particular CDR will vary depending on the sequence and size of the CDR. Based on the variable region amino acid sequence of an antibody, a person skilled in the art can routinely determine which residues constitute a particular CDR.
[0160] Table B: CDR Definition 1
[0161]
[0162]
[0163] 1 The numbering of all CDR definitions in Table A follows the numbering convention outlined by Kabat et al. (see below). 2 "AbM" with a lowercase "b" as used in Table A refers to CDRs as defined by Oxford Molecular's "AbM" antibody modeling software.
[0164] Kabat et al. also defined a numbering system that can be applied to the variable region sequence of any antibody. One of ordinary skill in the art can clearly assign this system of "Kabat numbering" to any variable region sequence, independent of any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system listed in Kabat et al., US Pat. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in the variable region of an antibody are in accordance with the Kabat numbering system.
[0165] In addition to CDR1 in VH, CDRs generally include amino acid residues that form hypervariable loops. CDRs also include "specificity determining residues" or "SDRs", which are residues that contact antigens. SDRs are included in CDR regions called shortened CDRs or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 (L1), 50-55 (L2), 89-96 (L3), 31-35B (H1), 50-58 (H2), and 95-102 (H3) (see Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)). Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., see above.
[0166] As used herein, the term "affinity matured" in the context of an antigen binding molecule (e.g., an antibody) refers to an antigen binding molecule that is derived from a reference antigen binding molecule, e.g., by mutation, binds to the same antigen, preferably to the same epitope, as the reference antibody; and has a higher affinity for the antigen than the reference antigen binding molecule. Affinity maturation generally involves modifying one or more amino acid residues in one or more CDRs of the antigen binding molecule. Typically, the affinity matured antigen binding molecule binds to the same epitope as the initial reference antigen binding molecule.
[0167] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1 (L1)-FR2-H2 (L2)-FR3-H3 (L3)-FR4.
[0168] For purposes herein, an "acceptor human framework" is a framework comprising an amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below. An acceptor human framework "derived" from a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.
[0169] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0170] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0171] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise at least one, typically substantially all, variable domains wherein the entire or substantially all HVRs (e.g., CDRs) correspond to those of a non-human antibody, and the entire or substantially all FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. Other forms of "humanized antibodies" encompassed by the present invention are those in which the constant region has been additionally modified or altered from that of the original antibody to generate properties in accordance with the present invention, particularly with respect to C1q binding and / or Fc receptor (FcR) binding.
[0172] A "human" antibody is an antibody that possesses an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell or derived from a non-human source utilizing a human antibody repertoire or other human antibody encoding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0173] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an antibody heavy chain containing at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. The IgG Fc region comprises IgG CH2 and IgG CH3 domains. The "CH2 domain" of a human IgG Fc region generally extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or a variant CH2 domain. The "CH3 domain" comprises the stretch of residues at the C-terminus of the CH2 domain in the Fc region (i.e., from an amino acid residue at about position 341 of IgG to an amino acid residue at about position 447). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having a "protuberance" ("knot") introduced in one chain thereof and a "cavity" ("hole") introduced correspondingly in the other chain thereof; see U.S. Patent No. 5,821,333, expressly incorporated herein by reference). As described herein, such variant CH3 domains can be used to promote heterodimerization of two different antibody heavy chains. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may be present or absent. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is in accordance with the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0174] The "knob-into-hole" technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide, such that the protuberance can be placed in the cavity, thereby promoting heterodimer formation and hindering homodimer formation. The protuberance is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity of the same or similar size as the protuberance is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller side chain (e.g., alanine or threonine). The protuberance and cavity can be generated by altering the nucleic acid encoding the polypeptide, for example, by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment, the knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other of the two subunits of the Fc domain. In yet another specific embodiment, the subunit comprising the knob modification in the Fc domain further comprises the amino acid substitution S354C, and the subunit comprising the hole modification in the Fc domain further comprises the amino acid substitution Y349C. The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).
[0175] "A region equivalent to the Fc region of an immunoglobulin" is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin and variants that have altered substitutions, additions, or deletions but do not substantially reduce the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular cytotoxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, JU et al., Science 247: 1306-10 (1990)).
[0176] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated uptake of antigens by antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0177] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc region of an antibody, initiates signaling events that stimulate cells bearing the receptor to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). One specific activating Fc receptor is human FcγRIIIa (see UniProt Accession No. P08637, version 141).
[0178] As used herein, the term "effector cell" refers to a group of lymphocytes that display effector module receptors (e.g., cytokine receptors) and / or Fc receptors on their surface, through which they bind to the Fc region of the effector module (e.g., cytokine) and / or antibody and promote the destruction of target cells (e.g., tumor cells). For example, effector cells can mediate cytotoxic or phagocytic effects. Effector cells include, but are not limited to, effector T cells such as CD8 + Cytotoxic T cells, CD4 + Helper T cells, γδ T cells, NK cells, lymphokine-activated killer (LAK) cells and macrophages / monocytes.
[0179] "Extraterrestrial domain" is a domain in a membrane protein that extends into the extracellular space (i.e., the space outside the target cell). The extraterrestrial domain is usually the part of the protein that initiates contact with the surface, which leads to signal transduction. Thus, the extraterrestrial domain of 4-1BBL as defined herein refers to the part of 4-1BBL that extends into the extracellular space (extracellular domain), but also includes a shorter part or fragment thereof that is responsible for trimerization and binding to the corresponding receptor 4-1BB. Thus, the term "extraterrestrial domain or fragment thereof of 4-1BBL" refers to the extracellular domain of 4-1BBL that forms the extracellular domain or the part thereof that is still able to bind to the receptor (receptor binding domain).
[0180] "4-1BBL" or "4-1BB ligand" or "CD137L" is a member of the costimulatory TNF ligand family that can costimulate T cell proliferation and cytokine production. Costimulatory TNF family ligands can costimulate TCR signals when interacting with their corresponding TNF receptors, and the interaction with their receptors leads to the recruitment of TNFR-associated factors (TRAFs), which initiate the signal transduction cascade leading to T cell activation. 4-1BBL is a type II transmembrane protein. It has been described that the complete or full-length 4-1BBL having the amino acid sequence of SEQ ID NO:66 forms a trimer on the surface of the cell. The formation of trimers is achieved by specific motifs in the outer domain of 4-1BBL. The motif is named "trimerization region" in this article. Amino acids 50-254 (SEQ ID NO:67) of the human 4-1BBL sequence form the extracellular domain of 4-1BBL, but even fragments thereof can form trimers. In a specific embodiment of the present invention, the term "exodomain of 4-1BBL or a fragment thereof" refers to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 4 (amino acids 52-254 of human 4-1BBL), SEQ ID NO: 1 (amino acids 71-254 of human 4-1BBL), SEQ ID NO: 3 (amino acids 80-254 of human 4-1BBL), SEQ ID NO: 2 (amino acids 85-254 of human 4-1BBL), SEQ ID NO: 5 (amino acids 71-248 of human 4-1BBL), SEQ ID NO: 6 (amino acids 85-248 of human 4-1BBL), SEQ ID NO: 7 (amino acids 80-248 of human 4-1BBL) and SEQ ID NO: 8 (amino acids 52-248 of human 4-1BBL), but other fragments of the exodomain capable of trimerization are also included herein.
[0181] As used herein, the term "4-1BB" or "CD137" refers to any native 4-1BB from any vertebrate source, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise specified. The term encompasses "full-length," unprocessed 4-1BB as well as any form of 4-1BB derived from processing in cells. The term also encompasses naturally occurring variants of 4-1BB, such as splice variants or allelic variants. An exemplary amino acid sequence of human 4-1BB is shown in SEQ ID NO: 68 (Uniprot Accession No. Q07011), an exemplary amino acid sequence of mouse 4-1BB is shown in SEQ ID NO: 69 (Uniprot Accession No. P20334), and an exemplary cynomolgus monkey 4-1BB (from macaque (Macaca mulatta)) amino acid sequence is shown in SEQ ID NO: 70 (Uniprot Accession No. F6W5G6).
[0182] The terms "anti-4-1BB antibody", "anti-4-1BB", "4-1BB antibody", and "antibody that specifically binds to 4-1BB" refer to an antibody that is capable of binding to 4-1BB with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent in targeting 4-1BB. In one embodiment, the extent of binding of the anti-4-1BB antibody to an unrelated, non-4-1BB protein is less than about 10% of the binding of the antibody to 4-1BB, as measured, for example, by radioimmunoassay (RIA) or flow cytometry (FACS). In certain embodiments, the antibody that binds to 4-1BB has a specific binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -6 M or less, e.g. 10 -68 M to 10 -13 M, for example 10 -8 M to 10 -10 The dissociation constant (K D For example, Urelumab is an anti-4-1BB antibody derived from antibody 20H4.9 and
[0183] The term "peptide linker" refers to a peptide comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example, (G4S) n ,(SG4) n or G4(SG4) nA peptide linker, wherein "n" is generally a number between 1 and 10, typically between 2 and 4, in particular 2, i.e., the peptide is selected from the group consisting of GGGGS (SEQ ID NO:81), GGGGSGGGGS (SEQ ID NO:82), SGGGGSGGGG (SEQ ID NO:83), and GGGGSGGGGSGGGG (SEQ ID NO:84), but also includes the sequence GSPGSSSSGS (SEQ ID NO:85), (G4S)3 (SEQ ID NO:86), (G4S)4 (SEQ ID NO:87), GSGSGSGS (SEQ ID NO:88), GSGSGNGS (SEQ ID NO:89), GGSGSGSG (SEQ ID NO:90), GGSGSG (SEQ ID NO:91), GGSG (SEQ ID NO:92), GGSGNGSG (SEQ ID NO:93), GGNGSGSG (SEQ ID NO:94) and GGNGSG (SEQ ID NO:95). Peptide linkers of particular interest are (G4S) (SEQ ID NO:81) and (G4S)2 (SEQ ID NO:82).
[0184] As used within this application, the term "amino acid" refers to the group of naturally occurring carboxyl α-amino acids, including alanine (three letter code: ala, single letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
[0185] "Fused" or "linked" means that the components (eg, a polypeptide and the external domain of 4-1BBL) are linked by peptide bonds, either directly or via one or more peptide linkers.
[0186] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage sequence identity, and without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percentage amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN.SAWI or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. However, for purposes herein, the sequence comparison computer program ALIGN-2 is used to generate % amino acid sequence identity values. The ALIGN-2 sequence comparison computer program was written by Genentech, and the source code has been submitted to the U.S. Copyright Office (Washington DC, 20559) with user documentation, registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is available to the public from Genentech, Inc. (South San Francisco, California), or can be compiled from source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged. In the case of amino acid sequence comparison using ALIGN-2, the % amino acid sequence identity of a given amino acid sequence A relative to, with, or against a given amino acid sequence B (or it can be expressed as a given amino acid sequence A having or containing a certain % amino acid sequence identity relative to, with, or against a given amino acid sequence B) is calculated as follows:
[0187] Multiply the fraction X / Y by 100
[0188] where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that in cases where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.
[0189] In certain embodiments, amino acid sequence variants of antigen binding molecules provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of an antigen binding molecule. Amino acid sequence variants of antigen binding molecules may be prepared by introducing suitable modifications into the nucleotide sequence encoding the molecule, or by peptide synthesis. Such modifications include, for example, deletion of residues within the amino acid sequence of an antibody, and / or insertion and / or substitution. Any combination of deletion, insertion, and substitution may be performed to obtain the final construct, provided that the final construct possesses desired characteristics, such as antigen binding. Sites of interest for substitution mutagenesis include HVR and framework (FR). Conservative substitutions are provided in Table C under the heading "Preferred Substitutions" and are further described below with reference to amino acid side chain categories (1) to (6). Amino acid substitutions may be introduced into the molecule of interest and the product screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0190] Table C
[0191]
[0192]
[0193] Amino acids can be grouped according to common side chain properties:
[0194] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
[0195] (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
[0196] (3) Acidic: Asp, Glu;
[0197] (4) Basic: His, Lys, Arg;
[0198] (5) Residues affecting chain orientation: Gly, Pro;
[0199] (6) Aromatic: Trp, Tyr, Phe.
[0200] Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.
[0201] The term "amino acid sequence variant" includes substantial variants in which there are amino acid substitutions in one or more hypervariable region residues of a parent antigen binding molecule (e.g., humanized or human antibodies). Generally, the resulting variants selected for further study will have changes (e.g., improvements) in certain biological properties relative to the parent antigen binding molecule (e.g., increased affinity, reduced immunogenicity) and / or will substantially retain certain biological properties of the parent antigen binding molecule. Exemplary substitution variants are affinity-matured antibodies, which can be conveniently generated, for example, using affinity maturation techniques based on phage display such as those described herein. In short, one or more CDR residues are mutated and the variant antigen binding molecules are displayed on phage and screened for specific biological activity (e.g., binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs, as long as such changes do not substantially reduce the ability of the antigen binding molecule to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in the CDRs. A method useful for identifying residues or regions in an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis", as described by Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, residues or groups of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitutions. Alternatively or in addition, the crystal structure of the antigen-antigen binding molecule complex is used to identify contact points between the antibody and the antigen. Such contact residues and neighboring residues can be targeted or eliminated as candidates for substitution. Variants can be screened to determine whether they contain desired properties.
[0202] Amino acid sequence insertions include amino and / or carboxyl terminal fusions ranging in length from 1 residue to polypeptides containing 100 or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antigen binding molecules with an N-terminal methionyl residue. Other insertion variants of the molecule include fusions to the N or C-termini of polypeptides that extend the serum half-life of the antigen binding molecule.
[0203] In certain embodiments, the antigen binding molecules provided herein are altered to increase or decrease the degree of antibody glycosylation. Glycosylation variants of the molecule can be conveniently obtained by changing the amino acid sequence so that one or more glycosylation sites are created or removed. In the case where the antigen binding molecule comprises an Fc region, the carbohydrate attached thereto can be changed. Natural antibodies produced by mammalian cells typically comprise branched biantennary oligosaccharides, which are generally attached to Asn297 of the CH2 domain of the Fc region by N-linkage. See, for example, Wright et al., TIBTECH 15: 26-32 (1997). Oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc in the "trunk" of the biantennary oligosaccharide structure. In some embodiments, modification of the oligosaccharides in the antigen binding molecule may be performed to create variants with certain improved properties. In one aspect, variants of antigen binding molecules having a carbohydrate structure lacking fucose attached (directly or indirectly) to the Fc region are provided. Such fucosylation variants may have improved ADCC function, see, for example, U.S. Patent Publication Nos. US2003 / 0157108 (Presta, L.) or US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Other variants of the antigen binding molecules of the present invention include those with bisected oligosaccharides, for example, wherein the biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and / or improved ADCC function, see, for example, WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).
[0204] "Engineering", particularly with the prefix "sugar", and the term "glycosylation engineering" includes metabolic engineering of the glycosylation apparatus of a cell, including genetic manipulation of oligosaccharide synthesis pathways to achieve altered glycosylation of glycoproteins expressed in the cell. In addition, glycosylation engineering includes mutations and the effects of the cellular environment on glycosylation. In one embodiment, glycosylation engineering is an alteration in glycosyltransferase activity. In a specific embodiment, engineering results in altered glucosaminyltransferase activity and / or fucosyltransferase activity. Glycosylation engineering can be used to obtain "host cells with increased GnTIII activity" (e.g., host cells that have been manipulated to express increased levels of one or more polypeptides with β(1,4)-N-acetylglucosaminyltransferase III (GnTIII) activity), "host cells with increased ManII activity" (e.g., host cells that have been manipulated to express increased levels of one or more polypeptides with α-mannosidase II (ManII) activity) or "host cells with reduced α(1,6) fucosyltransferase activity" (e.g., host cells that have been manipulated to express reduced levels of α(1,6) fucosyltransferase).
[0205] As used herein, the term "polypeptide having GnTIII activity" refers to a polypeptide capable of catalyzing the addition of N-acetylglucosamine (GlcNAc) residues to the β-linked mannoside of the trimannosyl core of an N-linked oligosaccharide in a β-1,4 linkage. This includes fusion polypeptides that exhibit enzymatic activity similar to, but not necessarily identical to, the activity of β(1,4)-N-acetylglucosaminyltransferase III, which is also known as β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase (EC 2.4.1.144) according to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB), as measured by a specific biological assay, with or without dose dependence. In cases where dose dependence does exist, it need not be equal to that of GnTIII, but rather, substantially similar to the dose dependence for a given activity compared to GnTIII (i.e., the candidate polypeptide will exhibit an activity that is either greater or no more than about 25-fold less, and preferably no more than about 10-fold less, and most preferably no more than about 3-fold less, relative to GnTIII).
[0206] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that leads to the lysis of antibody-coated target cells by immune effector cells. Target cells are cells to which antibodies or fragments thereof comprising an Fc region are generally specifically bound via the protein portion of the N-terminus of the Fc region. As used herein, the term "increased / decreased ADCC" is defined as an increase / decrease in the number of target cells lysed in a given time with a given concentration of antibody in the medium surrounding the target cells by the ADCC mechanism defined above, and / or a decrease / increase in the concentration of antibody in the medium surrounding the target cells required for the lysis of a given number of target cells in a given time by the ADCC mechanism. The increase / decrease in ADCC is relative to the ADCC mediated by the same antibody generated by the same type of host cells but not yet engineered using the same standard production, purification, formulation and storage methods (which are known to those skilled in the art). For example, ADCC mediated by an antibody produced by a host cell engineered by the methods described herein to have an altered glycosylation pattern (e.g., to express a glycosyltransferase, GnTIII or other glycosyltransferase) is increased relative to ADCC mediated by the same antibody produced by an unengineered host cell of the same type.
[0207] In certain aspects, the invention encompasses antibody variants that possess some, but not all, effector functions that make them desirable candidates for applications where the in vivo half-life of the antibody is important, while certain effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / ablation of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and therefore likely lacks ADCC activity), but retains FcRn binding ability. NK cells, the primary cells that mediate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-492 (1991). Non-limiting examples of in vitro assays for evaluating ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986); Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337; Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry). TM Nonradioactive cytotoxicity assays (Cell Technology, Inc., Mountain View, CA; and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest can be assessed in vivo, for example in an animal model such as that disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q binding assays can also be performed to confirm that the antibody cannot bind to C1q and therefore lacks CDC activity. See, for example, C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and M. J. Glennie, Blood 103: 2738-2743 (2004)). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18 (12): 1759-1769 (2006); WO 2013 / 120929 A1).
[0208] Antibodies with reduced effector function include those with substitutions of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant in which residues 265 and 297 are substituted with alanine (U.S. Pat. No. 7,332,581). Certain antibody variants with improved or reduced binding to FcRs are described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001)). In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, such as substitutions at Fc region positions 298, 333, and / or 334 (EU residue numbering).
[0209] In certain aspects, the antibody variant comprises an Fc region with one or more amino acid substitutions that weaken FcγR binding, such as substitutions at positions 234 and 235 (EU residue numbering) of the Fc region. In one aspect, the substitutions are L234A and L235A (LALA). In certain aspects, the antibody variant further comprises D265A and / or P329G in an Fc region derived from a human IgG1 Fc region. In one aspect, the substitutions are L234A, L235A, and P329G (LALA-PG) in an Fc region derived from a human IgG1 Fc region (see, e.g., WO 2012 / 130831). In another aspect, the substitutions are L234A, L235A, and D265A (LALA-DA) in an Fc region derived from a human IgG1 Fc region.
[0210] In some embodiments, alterations are made in the Fc region that result in altered (i.e., improved or reduced) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551; WO 99 / 51642; and Idusogie et al., J. Immunol. 164:4178-4184 (2000).
[0211] Antibodies with extended half-life and improved binding to the neonatal Fc receptor (FcRn) are described in US2005 / 0014934 (Hinton et al.), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). Those antibodies comprise an Fc region with one or more substitutions that improve the binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more of Fc region residues 238, 252, 254, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434 (e.g., substitution of Fc region residue 434) (see, e.g., U.S. Patent No. 7,371,826; Dall'Acqua, WF et al. J. Biol. Chem. 281 (2006) 23514-23524).
[0212] In certain aspects, the antibody variant comprises an Fc region having one or more amino acid substitutions that reduce FcRn binding (e.g., substitutions at positions 253, and / or 310, and / or 435 (EU residue numbering) of the Fc region). In certain aspects, the antibody variant comprises an Fc region having amino acid substitutions at positions 253, 310, and 435. In one aspect, the substitutions are I253A, H310A, and H435A in an Fc region derived from a human IgG1 Fc region. See, e.g., Grevys, A. et al., J. Immunol. 194 (2015) 5497-5508.
[0213] In another aspect, the antibody variant comprises an Fc region with one or more amino acid substitutions that reduce FcRn binding (e.g., substitutions at positions 310, and / or 433, and / or 436 (EU residue numbering) of the Fc region). In certain aspects, the antibody variant comprises an Fc region with amino acid substitutions at positions 310, 433, and 436. In one aspect, the substitutions are H310A, H433A, and Y436A in an Fc region derived from a human IgG1 Fc region (see, e.g., WO 2014 / 177460 Al).
[0214] In certain aspects, the antibody variant comprises an Fc region having one or more amino acid substitutions that improve FcRn binding, such as substitutions at positions 252, and / or 254, and / or 256 (EU residue numbering) of the Fc region. In certain embodiments, the antibody variant comprises an Fc region having amino acid substitutions at positions 252, 254, and 256. In one embodiment, the substitutions are M252Y, S254T, and T256E in an Fc region derived from a human IgG1 Fc region. See also Duncan and Winter, Nature 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO94 / 29351, which focus on other examples of Fc region variants.
[0215] In certain embodiments, it may be desirable to create a cysteine engineered variant of an antigen binding molecule of the invention, such as a "thioMAb", in which one or more residues of the molecule are replaced with cysteine residues. In a particular embodiment, the replaced residues occur at accessible sites of the molecule. By replacing those residues with cysteine, reactive thiol groups are thus placed at accessible sites of the antibody and can be used to conjugate the antibody to other modules such as drug modules or linker-drug modules to create immunoconjugates. In certain embodiments, any one or more of the following residues may be replaced with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antigen binding molecules may be generated as described, for example, in U.S. Patent No. 7,521,541.
[0216] In certain aspects, the antigen binding molecules provided herein can be further modified to contain additional non-proteinaceous modules known in the art and readily available. Modules suitable for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, propylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on the following considerations, including but not limited to the specific properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used for therapy under limited conditions, etc. In another aspect, a conjugate of an antibody and a non-proteinaceous moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, NW et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation can be of any wavelength, and includes but is not limited to wavelengths that are not harmful to ordinary cells, but heat the non-proteinaceous moiety to a temperature at which cells near the antibody-non-proteinaceous moiety are killed.
[0217] In another aspect, an immunoconjugate containing an antigen binding molecule of 4-1BBL provided herein can be obtained. An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules including, but not limited to, a cytotoxic agent.
[0218] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), virally derived RNA, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds, such as those found in peptide nucleic acids (PNA)). The term "nucleic acid molecule" refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.
[0219] An "isolated" nucleic acid molecule or polynucleotide means a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. For example, for the purposes of the present invention, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or polynucleotides purified (partially or substantially) in solution. Isolated polynucleotides include polynucleotide molecules contained in cells that normally contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or in a chromosomal location different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules generated synthetically. In addition, the polynucleotide or nucleic acid may be or may include a regulatory element, such as a promoter, a ribosome binding site, or a transcription terminator.
[0220] A nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to 5 point mutations per every 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or a plurality of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These changes in the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, either interspersed individually between residues in the reference sequence or interspersed in one or more consecutive groups within the reference sequence. In practice, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be routinely determined using known computer programs, such as those discussed above with respect to polypeptides (e.g., ALIGN-2).
[0221] The term "expression cassette" refers to a recombinantly or synthetically generated polynucleotide having a series of defined nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the invention comprises a polynucleotide sequence encoding a bispecific antigen binding molecule of the invention or a fragment thereof.
[0222] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule used to introduce a specific gene operably associated therewith into a target cell and direct expression. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. The expression vectors of the present invention comprise expression cassettes. The expression vectors allow for the transcription of large amounts of stable mRNA. Once the expression vector is within the target cell, the ribonucleic acid molecule or protein encoded by the gene is produced by the cell's transcription and / or translation machinery. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.
[0223] The terms "host cell", "host cell line", and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the progeny of such cells. Host cells include "transformants / transformants" and "transformed cells", which include primary transformed cells and progeny derived therefrom, regardless of the number of passages. Progeny may not be completely identical to the parent cell in terms of nucleic acid content, but may contain mutations. Mutant progeny with the same function or biological activity as screened or selected in the original transformed cell are included herein. Host cells are any type of cell system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, such as cultured mammalian cells, such as CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also transgenic animals, transgenic plants or cells contained in cultured plant or animal tissues.
[0224] An "effective amount" of an agent is that amount necessary to cause a physiological change in the cells or tissues to which it is administered.
[0225] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time, to achieve the desired therapeutic or preventive result. For example, a therapeutically effective amount of an agent eliminates, alleviates / reduces, delays, minimizes, or prevents the adverse effects of a disease.
[0226] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). Specifically, an individual or subject is a human.
[0227] The term "pharmaceutical composition" refers to a preparation which is in such form as to permit the biological activity of the active ingredient contained therein to be effective, and which contains no additional ingredients which are unacceptably toxic to a subject to which the formulation would be administered.
[0228] "Pharmaceutically acceptable excipients" refer to components of a pharmaceutical composition other than the active ingredient that are non-toxic to the subject. Pharmaceutically acceptable excipients include, but are not limited to, buffers, stabilizers, or preservatives.
[0229] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.
[0230] As used herein, "treatment" refers to clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed either for prevention or in the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, diminishing any direct or indirect pathological consequences of disease, preventing metastasis, slowing the rate of disease progression, ameliorating or palliating the disease state, and regression or improved prognosis. In some embodiments, the molecules of the invention are used to delay the onset of disease or slow the progression of disease.
[0231] As used herein, the term "cancer" refers to a proliferative disease, such as lymphoma or lymphocytic leukemia, or melanoma.
[0232] "B cell proliferative disorder" means a disease in which the number of B cells in a patient is increased compared to the number of B cells in a healthy subject, particularly wherein the increase in the number of B cells is the cause or hallmark of the disease. A "CD20-positive B cell proliferative disorder" is a B cell proliferative disorder in which B cells, particularly malignant B cells (other than normal B cells), express CD20. Exemplary B cell proliferative disorders include non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and some types of multiple myeloma (MM) and Hodgkin lymphoma (HL).
[0233] Exemplary 4-1BB agonists for use in the present invention
[0234] In particular, the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 used in combination with an anti-CD20 antibody is a molecule comprising 4-1BBL. In particular, the 4-1BB agonist used in the present invention comprises three 4-1BBL ectodomains or fragments thereof.
[0235] In a specific aspect, the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
[0236] It has been shown herein that a 4-1BB agonist is particularly useful if it comprises an antigen binding domain specific for a tumor target, particularly a target on a B cell. Thus, in another aspect, a 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19.
[0237] It has been further shown herein that a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 is not internalized into B cells by CD19 and does not lose its ability to interact with the tumor microenvironment. In yet another aspect, provided is a 4-1BB agonist that will not be internalized in B cells, thereby maintaining its activity.
[0238] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one module capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 is cross-reactive to cynomolgus monkeys, that is, the antigen binding domain capable of specifically binding to CD19 specifically binds to human and cynomolgus monkey CD19.
[0239] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one module capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V HCD19), comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain variable region (V L CD19), which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a VH domain, which comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL domain, which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0240] In one particular aspect, an antigen binding domain capable of specifically binding to CD19 comprises a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL domain comprising (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0241] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ...L More specifically, the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0242] In another aspect, the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably combining. In one aspect, the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain. In particular, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function. In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0243] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:
[0244] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0245] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0246] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0247] In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising:
[0248] (a) at least one Fab domain capable of specifically binding to CD19, and
[0249] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0250] The antigen binding molecule is characterized by
[0251] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0252] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0253] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to the VH or VL via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.
[0254] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:
[0255] (a) at least one Fab domain capable of specifically binding to CD19, comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19), and
[0256] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0257] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0258] In a specific aspect, the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0259] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0260] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0261] c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:39, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:40;
[0262] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:33, a first light chain comprising the amino acid sequence of SEQ ID NO:34, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41, and a second light chain comprising the amino acid sequence of SEQ ID NO:42;
[0263] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0264] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0265] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0266] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0267] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 48, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 49, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 50;
[0268] j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 47, a first light chain comprising the amino acid sequence of SEQ ID NO: 48, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0269] k) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and
[0270] l) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:48, a first heavy chain comprising the amino acid sequence of SEQ ID NO:51 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:52.
[0271] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:
[0272] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0273] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0274] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:
[0275] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0276] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker, and
[0277] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.
[0278] In a specific aspect, the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0279] (a) A molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53,
[0280] (b) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19) and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53;
[0281] (c) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 54, and
[0282] (d) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO:55.
[0283] In yet another aspect, the 4-1BB agonist is an anti-CD19 / anti-4-1BB bispecific antibody.
[0284] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises (a) a heavy chain variable region (V H FAP and light chain variable region (V LFAP), heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 96, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 97, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 98, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 99, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 100, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 101, or (b) a heavy chain variable region (V H FAP and light chain variable region (V L FAP), heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 102, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 103, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 104, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:105, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:106, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:107.
[0285] In one specific aspect, the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP and light chain variable region (V L FAP), heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 102, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 103, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 104, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:105, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:106, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:107.
[0286] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 111 L More specifically, the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 111 L FAP).
[0287] In another aspect, the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably combining. In one aspect, the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain. In particular, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function. In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0288] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:
[0289] (a) at least one antigen binding domain capable of specifically binding to FAP,
[0290] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0291] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0292] In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising:
[0293] (a) at least one Fab domain capable of specifically binding to FAP, and
[0294] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0295] The antigen binding molecule is characterized by
[0296] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0297] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0298] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to the VH or VL via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.
[0299] In a specific aspect, the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0300] A molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 112, a first light chain comprising the amino acid sequence of SEQ ID NO: 113, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42.
[0301] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:
[0302] (a) at least one antigen binding domain capable of specifically binding to FAP,
[0303] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0304] Particular bispecific antibodies are described in PCT Publication No. WO 2016 / 075278 A1 or PCT Publication No. WO 2016 / 156291 A1.
[0305] In yet another aspect, the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.
[0306] Preparation of Antigen Binding Molecules for Use in the Present Invention
[0307] In some aspects, the therapeutic agent used in combination comprises a multispecific antibody, such as a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificity for at least two different sites. In some aspects, the binding specificity is for different antigens. In some aspects, the binding specificity is for different epitopes on the same antigen. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0308] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature, 305:537 (1983)), WO 93 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and “knob-into-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). It can also be achieved by engineering electrostatic manipulation effects for generating antibody Fc-heterodimer molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229:81 (1985)); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology for generating bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al., 2003). al., J. Immunol., 152:5368 (1994)); and trispecific antibodies are prepared to generate multispecific antibodies as described, for example, in Tutt et al., J. Immunol. 147:60 (1991).
[0309] Also included herein are engineered antibodies having three or more functional antigen binding sites, including "octopus antibodies" (see, e.g., US 2006 / 0025576 A1).
[0310] The antibodies or fragments herein also include "dual-acting FAbs" or "DAFs" comprising antigen binding sites that bind to two different antigens (see, e.g., US2008 / 0069820). Also included herein are "Crossmab" antibodies (see, e.g., WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254).
[0311] Another technology used to generate bispecific antibody fragments is the "bispecific T cell engager" or The present invention relates to a method for preparing an antibody-binding fragment (see, for example, WO2004 / 106381, WO2005 / 061547, WO2007 / 042261, and WO2008 / 119567). This method utilizes two antibody variable domains arranged on a single polypeptide. For example, a single polypeptide chain comprises two single-chain Fv (scFv) fragments, each having a variable heavy chain (V) separated by a polypeptide linker. H ) domain and a variable light chain (V L ) domains, the length of the polypeptide linker being sufficient to allow intramolecular association between the two domains. The single polypeptide further comprises a polypeptide spacer sequence between the two scFv fragments. Each scFv recognizes a different epitope, and these epitopes can be specific for different cell types, such that cells of two different cell types come into close proximity or tethering when each scFv engages its cognate epitope. A specific embodiment of this approach comprises a scFv that recognizes a cell surface antigen expressed by an immune cell (e.g., a CD3 polypeptide on a T cell) joined to another scFv that recognizes a cell surface antigen expressed by a target cell (such as a malignant or tumor cell).
[0312] Because it is a single polypeptide, the bispecific T cell engager can be expressed using any prokaryotic or eukaryotic cell expression system known in the art (e.g., CHO cell line). However, specific purification techniques (see, e.g., EP1691833) may be necessary to separate monomeric bispecific T cell engagers from other multimeric species (which may have biological activities different from the predetermined activity of the monomer). In an exemplary purification scheme, a solution containing the secreted polypeptide is first subjected to metal affinity chromatography, and the polypeptide is eluted using a gradient of imidazole concentration. This eluate is further purified using anion exchange chromatography, and the polypeptide is eluted using a gradient of sodium chloride concentration. Finally, this eluate is subjected to size exclusion chromatography to separate monomeric and multimeric species. In one aspect, the bispecific bispecific antibody used in the present invention is composed of a single polypeptide chain comprising two single-chain Fv fragments (scFV) fused to each other via a peptide linker.
[0313] Fc domain modifications that reduce Fc receptor binding and / or effector function
[0314] The Fc domain of the antigen binding molecule of the present invention is composed of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can stably associate with each other.
[0315] The Fc domain confers favorable pharmacokinetic properties to the antigen binding molecules of the invention, including a long serum half-life and a favorable tissue-blood distribution ratio that contribute to better accumulation in target tissues. However, at the same time, this may lead to unwanted targeting of the bispecific antibodies of the invention to cells expressing Fc receptors rather than preferred antigen-bearing cells. Thus, in a specific aspect, the Fc domain of the antigen binding molecule of the invention exhibits reduced binding affinity to Fc receptors and / or reduced effector function compared to the native IgG1 Fc domain. In one aspect, Fc does not substantially bind to Fc receptors and / or does not induce effector function. In a specific aspect, the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc domain does not induce effector function. Reduced effector function may include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling that induces apoptosis, reduced dendritic cell maturation, or reduced T cell priming.
[0316] In certain aspects, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., substitution) at one or more amino acid positions.
[0317] In a specific aspect, the invention provides an antibody wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor, particularly an Fcγ receptor.
[0318] In one aspect, the Fc domain of an antibody of the invention comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to an Fc receptor and / or the effector function. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In particular, the Fc domain comprises amino acid substitutions at positions E233, L234, L235, N297, P331 and P329 (EU numbering). In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and / or 329 (EU numbering) of the IgG heavy chain. More particularly, provided is an antibody according to the invention comprising an Fc domain having amino acid substitutions L234A, L235A and P329G ("P329G LALA", EU numbering) in the IgG heavy chain. The amino acid substitutions L234A and L235A refer to so-called LALA mutations. The "P329G LALA" amino acid substitution combination almost completely eliminates Fcγ receptor binding of human IgG1 Fc domain and is described in International Patent Application Publication No. WO 2012 / 130831A1, which also describes methods for preparing such mutant Fc domains and methods for determining their properties such as Fc receptor binding or effector function.
[0319] Fc domains with reduced Fc receptor binding and / or effector function also include those with substitutions of one or more Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitutions of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
[0320] In another aspect, the Fc domain is an IgG4 Fc domain. Compared with IgG1 antibodies, IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), particularly an amino acid substitution S228P. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G (EU numbering). Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are also described in WO 2012 / 130831.
[0321] Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The correct nucleotide changes can be verified, for example, by sequencing.
[0322] Binding to Fc receptors can be readily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare), and Fc receptors such as those obtainable by recombinant expression. Alternatively, the binding affinity of an Fc domain or a cell-activating antibody comprising an Fc domain to an Fc receptor can be assessed using a cell line known to express a specific Fc receptor, such as human NK cells expressing the FcγIIIa receptor.
[0323] The effector function of the Fc domain or the antibody of the present invention comprising the Fc domain can be measured by methods known in the art. A suitable assay for measuring ADCC is described herein. Other examples of in vitro assays for evaluating ADCC activity of molecules of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, a non-radioactive assay method can be used (see, for example, ACTI TM non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc., Mountain View, CA); and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest can be assessed in vivo, for example in an animal model, such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).
[0324] In some aspects, the binding of the Fc domain to complement components, specifically C1q, is reduced. Thus, in some embodiments in which the Fc domain is engineered to have reduced effector function, the reduced effector function comprises reduced CDC. A C1q binding assay can be performed to determine whether the bispecific antigen binding molecules of the invention are capable of binding to C1q and thus have CDC activity (see, e.g., C1q and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402). To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).
[0325] Fc domain modifications that promote heterodimerization
[0326] The bispecific antigen binding molecules of the present invention comprise different antigen binding sites fused to one or the other of the two subunits of the Fc domain, so that the two subunits of the Fc domain can be contained in two non-identical polypeptide chains. The recombinant co-expression of these polypeptides and the subsequent dimerization result in several possible combinations of the two polypeptides. In order to improve the yield and purity of the bispecific antibodies of the present invention in recombinant production, it would be advantageous to introduce modifications that promote the association of the desired polypeptides in the Fc domain of the bispecific antigen binding molecules of the present invention.
[0327] Thus, in a particular aspect, the present invention relates to a bispecific antigen-binding molecule comprising (a) at least one module capable of specifically binding to a tumor-associated antigen, in particular CD19 or FAP, (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0328] Wherein the antigen binding molecule is characterized in that the first polypeptide comprises two outer domains or two fragments of a TNF ligand family member connected to each other by a peptide linker and that the second polypeptide comprises only one outer domain or a fragment thereof of the TNF ligand family member, and (c) an Fc domain consisting of the first and second subunits capable of stabilizing the union, wherein the Fc domain comprises a modification that promotes the union of the first and second subunits of the Fc domain. The site of the most extensive protein-protein interaction between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one aspect, the modification is in the CH3 domain of the Fc domain.
[0329] In a specific aspect, the modification is a so-called "knob-into-hole" modification, comprising a "knob" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain. Thus, the present invention relates to an antigen binding molecule comprising (a) at least one module capable of specifically binding to a tumor-associated antigen, in particular CD19 or FAP, (b) a first and a second polypeptide linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL extracellular domains or two fragments thereof linked to each other by a peptide linker and in that the second polypeptide comprises only one of the 4-1BBL extracellular domains or fragments thereof, and (c) an Fc domain consisting of a first and a second subunit capable of stably combining, wherein according to the knob-into-hole method, the first subunit of the Fc domain comprises a knob and the second subunit of the Fc domain comprises a hole. In a specific aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to the Kabat EU index).
[0330] The "knob-into-hole" technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide, so that the protuberance can be placed in the cavity, thereby promoting heterodimer formation and hindering homodimer formation. The protuberance is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity of the same or similar size as the protuberance is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller side chain (e.g., alanine or threonine).
[0331] Thus, in one aspect, an amino acid residue is replaced with an amino acid residue having a larger side chain volume in the CH3 domain of the first subunit of the Fc domain of the bispecific antigen binding molecule of the present invention, thereby generating a protuberance in the CH3 domain of the first subunit, which can be placed in a cavity in the CH3 domain of the second subunit, and an amino acid residue is replaced with an amino acid residue having a smaller side chain volume in the CH3 domain of the second subunit of the Fc domain, thereby generating a cavity in the CH3 domain of the second subunit, in which the protuberance in the CH3 domain of the first subunit can be placed. The protuberance and cavity can be generated by changing the nucleic acid encoding the polypeptide, for example, by site-specific mutagenesis, or by peptide synthesis. In a specific aspect, the threonine residue at position 366 is replaced with a tryptophan residue in the CH3 domain of the first subunit of the Fc domain (T366W), and the tyrosine residue at position 407 is replaced with a valine residue in the CH3 domain of the second subunit of the Fc domain (Y407V). In one aspect, the threonine residue at position 366 is additionally replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A) in the second subunit of the Fc domain.
[0332] In yet another aspect, the serine residue at position 354 is additionally replaced with a cysteine residue in the first subunit of the Fc domain (S354C), and the tyrosine residue at position 349 is additionally replaced with a cysteine residue in the second subunit of the Fc domain (Y349C). The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc domain that further stabilizes the dimer (Carter, J Immunol Methods 248, 7-15 (2001)). In a specific aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
[0333] In an alternative aspect, modifications that promote association of the first and second subunits of the Fc domain include modifications that mediate electrostatic manipulation effects, such as described in PCT Publication WO 2009 / 089004. Generally, this approach involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues such that homodimer formation becomes electrostatically unfavorable but heterodimerization becomes electrostatically favorable.
[0334] The C-terminus of the heavy chain of the bispecific antibody reported herein may be a complete C-terminus ending with the amino acid residue PGK. The C-terminus of the heavy chain may be a shortened C-terminus in which one or two C-terminal amino acid residues have been removed. In a preferred aspect, the C-terminus of the heavy chain is a shortened C-terminus ending with PG. In one aspect of all aspects reported herein, the bispecific antibody comprising a heavy chain including a C-terminal CH3 domain as specified herein comprises a C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to the Kabat EU index). In one aspect of all aspects reported herein, the bispecific antibody comprising a heavy chain including a C-terminal CH3 domain as specified herein comprises a C-terminal glycine residue (G446, numbering according to the Kabat EU index).
[0335] Modifications in the Fab domain
[0336] In one aspect, the present invention relates to an antigen binding molecule containing 4-1BBL, which comprises (a) a Fab fragment capable of specifically binding to a tumor-associated antigen, in particular CD19 or FAP, (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL outer domains or two fragments thereof connected to each other by a peptide linker and that the second polypeptide comprises only one 4-1BBL outer domain or a fragment thereof, and (c) an Fc domain consisting of a first and a second subunit capable of stably combining, wherein in one of the Fab fragments, either the variable domains VH and VL or the constant domains CH1 and CL are exchanged. The bispecific antibody is prepared according to the Crossmab technology.
[0337] Multispecific antibodies with domain replacement / exchange in one binding arm (CrossMab VH-VL or CrossMab CH-CL) are described in detail in WO2009 / 080252 and Schaefer, W. et al., PNAS, 108 (2011) 11187-1191. They clearly reduce the side products caused by the mispairing of the light chain against the first antigen with the wrong heavy chain against the second antigen (compared to the approach without such domain exchange).
[0338] In one aspect, the present invention relates to a bispecific antigen-binding molecule comprising (a) a first Fab fragment capable of specifically binding to CD19, (b) a first and a second polypeptide linked to each other by a disulfide bond, wherein the antigen-binding molecule is characterized in that the first polypeptide comprises two 4-1BBL extracellular domains or two fragments thereof linked to each other by a peptide linker and in that the second polypeptide comprises only one 4-1BBL extracellular domain or a fragment thereof, and wherein each of them is linked to a CH1 or CL domain, and (c) an Fc domain composed of a first and a second subunit capable of stably combining, wherein the constant domains CL and CH1 adjacent to 4-1BBL are replaced with each other so that the CH1 domain is part of the light chain and the CL domain is part of the heavy chain.
[0339] In another aspect, the present invention relates to a bispecific antigen binding molecule comprising (a) two light chains and two heavy chains of an antibody comprising two Fab fragments and Fc domains capable of specifically binding to a co-stimulatory TNF receptor family member, and (b) two additional Fab fragments capable of specifically binding to a target cell antigen, wherein each of the additional Fab fragments is connected to the C-terminus of the heavy chain of (a) via a peptide linker. In a specific aspect, the additional Fab fragment is a Fab fragment in which the variable domains VL and VH are replaced with each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.
[0340] In another aspect, and in order to further improve the correct pairing, a bispecific antigen binding molecule comprising (a) a first Fab fragment capable of specifically binding to CD19, (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL outer domains or two fragments thereof connected to each other by a peptide linker and that the second polypeptide comprises only one 4-1BBL outer domain or a fragment thereof, and wherein each of them is connected to a CH1 or CL domain, and (c) a bispecific antigen binding molecule of an Fc domain consisting of a first and a second subunit capable of stably combining may contain amino acid substitutions with different charges (so-called "charged residues"). These modifications are introduced in cross- or non-cross-CH1 and CL domains. In a specific aspect, the present invention relates to a bispecific antigen binding molecule, wherein the amino acid at position 123 (EU numbering) in one of the CL domains is replaced by arginine (R) and the amino acid at position 124 (EU numbering) is replaced by lysine (K) and wherein the amino acids at position 147 (EU numbering) and position 213 (EU numbering) in one of the CH1 domains are replaced by glutamic acid (E).
[0341] More particularly, the present invention relates to a bispecific antigen-binding molecule comprising a Fab, wherein the amino acid at position 123 (EU numbering) in the CL domain adjacent to a TNF ligand family member is replaced by arginine (R) and the amino acid at position 124 (EU numbering) is replaced by lysine (K), and wherein the amino acids at position 147 (EU numbering) and position 213 (EU numbering) in the CH1 domain adjacent to a TNF ligand family member are replaced by glutamic acid (E).
[0342] Polynucleotide
[0343] The present invention further provides an isolated polynucleotide encoding a bispecific antibody or fragment thereof as described herein.
[0344] The isolated polynucleotide encoding the antibody of the present invention can be expressed as a single polynucleotide encoding the entire antigen binding molecule or as a plurality of (e.g., two or more) polynucleotides that are co-expressed. The polypeptides encoded by the co-expressed polynucleotides can be combined via, for example, disulfide bonds or other means to form a functional antigen binding molecule. For example, the light chain portion of an immunoglobulin and the heavy chain portion of an immunoglobulin can be encoded by separate polynucleotides. When co-expressed, the heavy chain polypeptide will combine with the light chain polypeptide to form an immunoglobulin.
[0345] In some aspects, the isolated polynucleotide encodes the entire antibody according to the invention as described herein. In other embodiments, the isolated polynucleotide encodes the polypeptide contained in the antibody according to the invention as described herein.
[0346] In certain embodiments, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the invention is RNA, for example in the form of messenger RNA (mRNA). The RNA of the invention may be single-stranded or double-stranded.
[0347] Recombination methods
[0348] Bispecific antibodies as used in the present invention can be obtained by, for example, solid-state peptide synthesis (e.g., Merrifield solid phase synthesis) or recombinant production. For recombinant production, one or more polynucleotides encoding, for example, antibodies or polypeptide fragments thereof as described above are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such polynucleotides can be easily isolated and sequenced using conventional procedures. In one aspect of the present invention, a vector comprising one or more polynucleotides of the present invention is provided, preferably an expression vector. Methods well known to those skilled in the art can be used to construct an expression vector containing the coding sequence of the antibody (fragment) together with appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, synthetic technology, and in vivo recombination / genetic recombination. See, for example, Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, NY (1989) described in the technology. The expression vector may be part of a virus, a plasmid, or may be a nucleic acid fragment. The expression vector includes an expression cassette in which a polynucleotide encoding an antibody or a polypeptide fragment thereof (i.e., a coding region) is cloned in operable association with a promoter and / or other transcription or translation control elements. As used herein, a "coding region" is a portion of a nucleic acid consisting of codons that are translated into amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not translated into amino acids, it may be considered as part of the coding region if present, but any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, 5' and 3' untranslated regions, and the like are not part of the coding region. Two or more coding regions may be present in a single polynucleotide construct, such as on a single vector, or in separate polynucleotide constructs, such as on separate (different) vectors. Moreover, any vector may contain a single coding region, or may contain two or more coding regions, for example, a vector of the present invention may encode one or more polypeptides that are separated into final proteins post-translationally or co-translationally via proteolytic cleavage. In addition, the vectors, polynucleotides, or nucleic acids of the present invention may encode heterologous coding regions, either fused or unfused with polynucleotides encoding the antibodies or polypeptide fragments thereof, or variants or derivatives thereof of the present invention. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains.Operable association is such that when a gene product, such as a coding region for a polypeptide, is so associated with one or more regulatory sequences, the expression of the gene product is placed under the influence or control of the regulatory sequences. Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated" if the induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the connection between the two DNA fragments does not interfere with the ability of the expression regulatory sequence to direct the expression of the gene product or the ability of the DNA template to be transcribed. Thus, if the promoter is able to affect the transcription of a nucleic acid encoding a polypeptide, the promoter region and the nucleic acid will be operably associated. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. In addition to the promoter, other transcription control elements, such as enhancers, operators, repressors, and transcription termination signals may be operably associated with the polynucleotide to direct cell-specific transcription.
[0349] Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, but are not limited to, transcription control regions that function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegalovirus (e.g., immediate early promoter, together with intron A), simian virus 40 (e.g., early promoter), and retroviruses (such as, for example, Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone, and rabbit alpha globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers and inducible promoters (e.g., tetracycline inducible promoters). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to, ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly internal ribosome entry sites or IRES, also known as CITE sequences). The expression cassette may also include other features, such as an origin of replication, and / or chromosomal integration elements, such as retroviral long terminal repeats (LTRs), or adeno-associated virus (AAV) inverted terminal repeats (ITRs).
[0350] The polynucleotide and nucleic acid coding regions of the present invention may be combined with additional coding regions encoding secretory or signal peptides that direct the secretion of the polypeptides encoded by the polynucleotides of the present invention. For example, if secretion of an antibody or polypeptide fragment thereof is desired, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding the antibody or polypeptide fragment thereof of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein once the export of the growing protein chain across the rough endoplasmic reticulum is initiated. Those of ordinary skill in the art know that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide that is cleaved from the translated polypeptide to generate a secreted or "mature" form of the polypeptide. In certain embodiments, a native signal peptide is used, such as an immunoglobulin heavy or light chain signal peptide, or a functional derivative of the sequence that retains the ability to direct the secretion of a polypeptide to which it is operably associated. Alternatively, a heterologous mammalian signal peptide or a functional derivative thereof may be used. For example, the wild-type leader sequence may be replaced with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.
[0351] DNA encoding short protein sequences that can be used to facilitate later purification (eg, a histidine tag) or to aid in labeling of the fusion protein may be included within or at the end of a polynucleotide encoding an antibody or polypeptide fragment thereof of the invention.
[0352] In yet another aspect of the invention, a host cell comprising one or more polynucleotides of the invention is provided. In certain embodiments, a host cell comprising one or more vectors of the invention is provided. The polynucleotides and vectors may incorporate any of the features described herein for the polynucleotides and vectors, respectively, singly or in combination. In one aspect, the host cell comprises (e.g., has been transformed or transfected) a vector comprising a polynucleotide encoding (a portion of) an antibody of the invention. As used herein, the term "host cell" refers to any type of cell system that can be engineered to produce a fusion protein of the invention or a fragment thereof. Host cells suitable for replication and support expression of antigen-binding molecules are well known in the art. Such cells can be appropriately transfected or transduced with a specific expression vector, and large quantities of cells containing the vector can be cultured for inoculation of large-scale fermenters to obtain sufficient quantities of antigen-binding molecules for clinical use. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli, or various eukaryotic cells, such as Chinese hamster ovary (CHO) cells, insect cells, and the like. For example, polypeptides can be produced in bacteria, particularly when glycosylation is not required. After expression, the polypeptide can be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding polypeptides, including fungi and yeast strains whose glycosylation pathways have been "humanized" to produce polypeptides with partial or complete human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).
[0353] Suitable host cells for expressing (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TMTechniques). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed with SV40 (COS-7), human embryonic kidney cell lines (e.g., 293 or 293T cells as described in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (e.g., TM4 cells as described in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described in Mather et al., Annals NY Acad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, such as cultured mammalian cells, yeast cells, insect cells, bacterial cells and plant cells, to name a few, but also transgenic animals, transgenic plants or cells contained in cultured plant or animal tissues. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) cell, or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). Standard techniques for expressing foreign genes in these systems are known in the art. Cells that express a polypeptide comprising either a heavy or light chain of an immunoglobulin can be engineered to also express another immunoglobulin chain, such that the expressed product is an immunoglobulin having both a heavy and light chain.
[0354] In one aspect, a method for producing an antibody or a polypeptide fragment thereof of the present invention is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding the antibody or a polypeptide fragment thereof as provided herein under conditions suitable for expression of the antibody or a polypeptide fragment thereof of the present invention, and recovering the antibody or a polypeptide fragment thereof of the present invention from the host cell (or host cell culture fluid).
[0355] In certain embodiments, the module (e.g., Fab fragment) capable of specifically binding to a target cell antigen that forms part of an antigen binding molecule comprises at least an immunoglobulin variable region capable of binding to an antigen. The variable region may form part of and be derived from a natural or non-naturally occurring antibody and its fragment. Methods for generating polyclonal antibodies and monoclonal antibodies are well known in the art (see, e.g., Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988). Non-naturally occurring antibodies may be constructed using solid phase peptide synthesis, may be recombinantly generated (e.g., as described in U.S. Patent No. 4,186,567), or may be obtained, for example, by screening a combinatorial library comprising a variable heavy chain and a variable light chain (see, e.g., U.S. Patent No. 5,969,108 to McCafferty).
[0356] Immunoglobulins of any animal species can be used in the present invention. Non-limiting immunoglobulins useful in the present invention can be of murine, primate, or human origin. If the fusion protein is intended for human use, a chimeric form of the immunoglobulin can be used, in which the constant region of the immunoglobulin is from a human. Humanized or fully human forms of immunoglobulins can also be prepared according to methods known in the art (see, for example, U.S. Patent No. 5,565,332 to Winter). Humanization can be achieved by a variety of methods, including but not limited to (a) grafting non-human (e.g., donor antibody) CDRs onto human (e.g., acceptor antibody) frameworks and constant regions with or without retaining key framework residues (e.g., those important for retaining excellent antigen binding affinity or antibody function), (b) grafting only non-human specific determining regions (SDRs or a-CDRs; residues critical for antibody-antigen interactions) onto human frameworks and constant regions, or (c) transplanting entire non-human variable domains, but "masking" them with human-like segments by replacing surface residues.Humanized antibodies and methods for generating them are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and in, e.g., Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR(a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing "surface remodeling"); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing the "guided selection" approach for FR shuffling). The specific immunoglobulins according to the present invention are human immunoglobulins. Human antibodies and human variable regions can be generated using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies generated by the hybridoma method (see, e.g., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).Human antibodies and human variable regions can also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see, e.g., Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions can also be produced by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see, e.g., Hoogenboom et al., in Methods in Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phage typically display antibody fragments either as single-chain Fv (scFv) fragments or as Fab fragments.
[0357] In some aspects, antibodies are engineered to have enhanced binding affinity according to methods disclosed in, for example, PCT Publication WO 2012 / 020006 (see Examples for affinity maturation) or U.S. Patent Application Publication No. 2004 / 0132066. The ability of the antigen-binding molecules of the present invention to bind to specific antigenic determinants can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance technology (Liljeblad et al., Glyco J 17, 323-329 (2000))), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competition assays can be used to identify antigen-binding molecules that compete with reference antibodies for binding to specific antigens. In certain embodiments, the epitope (e.g., linear or conformational epitope) bound by such competitive antigen-binding molecules is the same as that bound by the reference antigen-binding molecule. Detailed exemplary methods for mapping epitopes bound by antigen binding molecules are provided in Morris (1996) "Epitope Mapping Protocols", in Methods in Molecular Biology vol.66 (Humana Press, Totowa, NJ). In an exemplary competitive assay, an immobilized antigen is incubated in a solution containing a first labeled antigen binding molecule and a second unlabeled antigen binding molecule (testing its ability to compete with the first antigen binding molecule for binding antigen). The second antigen binding molecule may be present in a hybridoma supernatant. As a control, the immobilized antigen is incubated in a solution containing the first labeled antigen binding molecule but not the second unlabeled antigen binding molecule. After incubation under conditions that allow the first antibody to bind to the antigen, excess unbound antibodies are removed, and the amount of the label associated with the immobilized antigen is measured. If the amount of the label associated with the immobilized antigen in the test sample is substantially reduced relative to the control sample, this indicates that the second antigen binding molecule competes with the first antigen binding molecule for binding antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manualch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0358] The antibodies of the present invention prepared as described herein can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and will be apparent to those skilled in the art. For affinity chromatography purification, an antibody, ligand, receptor, or antigen that binds to the antigen binding molecule can be used. For example, for affinity chromatography purification of the fusion protein of the present invention, a matrix with protein A or protein G can be used. The antigen binding molecules can be separated using sequential protein A or G affinity chromatography and size exclusion chromatography essentially as described in the Examples. The purity of the antigen binding molecule or its fragment can be determined by any of a variety of well-known analytical methods, including gel electrophoresis, high pressure liquid chromatography, and the like. For example, the antigen binding molecules containing 4-1BBL expressed as described in the Examples are shown to be intact and properly assembled, as demonstrated by reducing and non-reducing SDS-PAGE.
[0359] Determination method
[0360] The antigen binding molecules provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.
[0361] 1. Affinity Assay
[0362] The affinity of the bispecific antigen binding molecules provided herein for the corresponding receptors can be determined by surface plasmon resonance (SPR) according to the methods set forth in the examples, using standard instruments such as a BIAcore instrument (GE Healthcare), and receptors or target proteins (such as those obtainable by recombinant expression). The affinity of the bispecific antigen binding molecules for target cell antigens can also be determined by surface plasmon resonance (SPR), using standard instruments such as a BIAcore instrument (GE Healthcare), and receptors or target proteins (such as those obtainable by recombinant expression). For CD19-4-1BBL antigen binding molecules, the methods have been described in more detail in International Patent Application Publication No. WO 2016 / 075278 A1. According to one aspect, at 25°C using K was measured by surface plasmon resonance using a T100 machine (GE Healthcare). D .
[0363] 2. Binding and other assays
[0364] In one aspect, the CD19-4-1BBL antigen binding molecule reported herein is tested for its antigen binding activity as described in more detail in Example 2.
[0365] 3. Activity Assay
[0366] In one aspect, an assay for identifying the biological activity of a CD19-4-1BBL antigen binding molecule is provided. The biological activity may include, for example, inhibition of B cell proliferation or killing of B cells. Antibodies having such biological activity in vivo and / or in vitro are also provided. For CD19-4-1BBL antigen binding molecules, certain methods are described in more detail in International Patent Application Publication No. WO 2016 / 075278A1.
[0367] In certain embodiments, the antibodies reported herein are tested for such biological activities.
[0368] Pharmaceutical compositions, formulations and routes of administration
[0369] In yet another aspect, the present invention provides a pharmaceutical composition comprising a 4-1BB agonist and an anti-CD20 antibody provided herein comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, for example, for use in any of the following treatment methods. In one aspect, the pharmaceutical composition comprises a 4-1BB agonist and at least one pharmaceutically acceptable excipient provided herein comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a second drug comprising an anti-CD20 antibody. In another embodiment, the pharmaceutical composition comprises a 4-1BB agonist and at least one pharmaceutically acceptable excipient provided herein comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a second drug comprising an anti-CD20 antibody and at least one additional therapeutic agent, such as described below.
[0370] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more antigen binding molecules described herein dissolved or dispersed in a pharmaceutically acceptable excipient. The phrase "pharmaceutically or pharmaceutically acceptable" refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e., do not produce adverse, allergic or other undesirable reactions when properly administered to animals, such as, for example, humans. The preparation of pharmaceutical compositions containing at least one antibody and optionally additional active ingredients will be known to those skilled in the art in light of this disclosure, such as Remington's Pharmaceutical Sciences, 18 thEd. Mack Printing Company, 1990, exemplified, incorporated herein by reference. In particular, the composition is a lyophilized formulation or an aqueous solution. As used herein, "pharmaceutically acceptable excipients" include any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as would be known to one of ordinary skill in the art.
[0371] Parenteral compositions include those designed for administration by injection, such as subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal or intraperitoneal injection. For injection, the antigen binding molecules of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulation agents, such as suspending, stabilizing and / or dispersing agents. Alternatively, the fusion protein may be in powder form for constitution with a suitable medium, such as sterile pyrogen-free water, before use. As required, a sterile injectable solution is prepared by incorporating the fusion protein of the present invention in a suitable solvent in the required amount together with a variety of other components listed below. Sterility can be easily achieved, for example, by filtering through a sterile filter membrane. Generally, dispersions are prepared by incorporating a variety of sterilized active components into a sterile medium containing a basic dispersion medium and / or other components. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsions, the preferred method of preparation is vacuum drying or freeze drying techniques, which produce a powder of the active ingredient plus any additional desired ingredients from a liquid medium which has been previously sterile filtered. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose prior to injection. The composition must be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept to a minimum at safe levels, for example less than 0.5 ng / mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin. , gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, dextran, and the like. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to allow the preparation of highly concentrated solutions. In addition, suspensions of the active compound may be prepared as suitable oily injection suspensions.Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
[0372] The active ingredient may be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained release formulations may be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, the matrix being in the form of a shaped article, such as a film, or microcapsules. In certain embodiments, prolonged absorption of the injectable composition may be achieved by using an agent that delays absorption in the composition, such as, for example, aluminum monostearate, gelatin, or a combination thereof.
[0373] Exemplary pharmaceutically acceptable excipients herein further include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), for example human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 ( Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use (including rHuPH20) are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
[0374] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0375] In addition to the compositions described previously, the antibodies can also be formulated as depot preparations. Such long-acting formulations can be administered by implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the fusion protein can be formulated with a suitable polymeric or hydrophobic material (e.g., as an emulsion in an acceptable oil) or an ion exchange resin, or as a sparingly soluble derivative, e.g., as a sparingly soluble salt.
[0376] Pharmaceutical compositions comprising antigen binding molecules of the present invention can be manufactured by conventional mixing, dissolving, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions can be prepared in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or adjuvants that facilitate processing of proteins into pharmaceutically usable preparations. Appropriate formulations depend on the selected route of administration.
[0377] The 4-1BB agonists provided herein comprising at least one antigen binding domain capable of specifically binding to CD19 can be formulated into compositions in free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of free acids or bases. These include acid addition salts, such as those formed with free amino groups of proteinaceous compositions or those formed with inorganic acids such as, for example, hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, oxalic acid, tartaric acid or mandelic acid. Salts formed with free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium hydroxide, potassium, ammonium, calcium or iron; or organic bases, such as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than the corresponding free base forms.
[0378] The compositions herein may also contain more than one active ingredient, where required for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts effective for the intended purpose.
[0379] In one aspect, a pharmaceutical composition is provided, comprising a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and a pharmaceutically acceptable excipient, and a second drug comprising an anti-CD20 antibody, as described herein. In a particular aspect, the pharmaceutical composition is used for treating B cell proliferative disorders, particularly selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin lymphoma (HL).
[0380] Formulations to be used for in vivo administration are generally sterile. Sterility can be readily accomplished, for example, by filtration through sterile filtration membranes.
[0381] Administration of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and an anti-CD20 antibody provided herein
[0382] Can be administered by any suitable means (including parenteral, intrapulmonary, and intranasal, and if desired for local treatment, intralesional administration) comprising at least one antigen binding domain capable of specifically binding CD19 4-1BB agonist and anti-CD20 antibody (both referred to as substances herein). However, with respect to therapeutic agents administered by parenteral (particularly intravenous) infusion, the method of the present invention is particularly useful.
[0383] Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Depending in part on whether the administration is short-term or long-term, dosing can be carried out by any suitable route (e.g., by injection, such as intravenous or subcutaneous injection). Various dosing schedules are contemplated herein, including but not limited to single administration or multiple administrations at multiple time points, push administration, and pulse infusion. In one embodiment, the therapeutic agent is administered parenterally (particularly intravenously). In a specific embodiment, the substance is administered by intravenous infusion. In another aspect, the substance is administered subcutaneously.
[0384] Both the 4-1BB agonist and the anti-CD20 antibody, which contain at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the site of drug delivery, the method of administration, the schedule of administration, and other factors known to medical practitioners. Both the 4-1BB agonist and the anti-CD20 antibody, which contain at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, need not be formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of therapeutic agent present in the formulation, the type of condition or treatment, and the other factors discussed above. These are generally used in the same dosages and administration routes as described herein, or in about 1-99% of the dosages described herein, or in any dosage and any route determined empirically / clinically to be appropriate.
[0385] For the prevention or treatment of disease, the appropriate dosage of the 4-1BB agonist and anti-CD20 antibody (when used in combination or with one or more other additional therapeutic agents) provided herein comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, will depend on the type of disease to be treated, the type of 4-1BB agent, the severity and course of the disease, whether the two agents are administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the therapeutic agent, and the discretion of the attending physician. Each substance is appropriately administered to the patient in one or a series of treatments. Depending on the type and severity of the disease, a substance of about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg-10 mg / kg) may be an initial candidate dose for administration to the subject, for example, whether by one or more separate administrations or by continuous infusion. Depending on the factors mentioned above, a typical daily dose may range from about 1 μg / kg to 100 mg / kg or more. For repeated administration for several days or longer, depending on the condition, treatment generally continues until the desired disease symptom containment occurs. An exemplary dose of each substance would be in the range of about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg or 10 mg / kg (or any combination thereof) may be administered to the subject. Such doses may be administered intermittently, for example, weekly, biweekly, or every three weeks (e.g., so that the subject receives about 2 to about 20, or, for example, about 6 doses of the therapeutic agent). A higher initial loading dose may be administered, followed by one or more lower doses, or a lower initial dose, followed by one or more higher doses. An exemplary dosing regimen comprises administering an initial dose of about 10 mg, followed by a biweekly dose of about 20 mg of the therapeutic agent. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
[0386] In one aspect, the administration of both a 4-1BB agonist and an anti-CD20 antibody comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, is a single administration. In certain aspects, the administration of the substance is two or more administrations. In one such aspect, the substance is administered weekly, every two weeks, or every three weeks, particularly every two weeks. In one aspect, the substance is administered in a therapeutically effective amount. In one aspect, the substance is administered at a dose of about 50 μg / kg, about 100 μg / kg, about 200 μg / kg, about 300 μg / kg, about 400 μg / kg, about 500 μg / kg, about 600 μg / kg, about 700 μg / kg, about 800 μg / kg, about 900 μg / kg, or about 1000 μg / kg. In one embodiment, a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, is administered at a higher dose than the dose of the 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, in a corresponding treatment regimen without the administration of an anti-CD20 antibody. In one aspect, the administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, provided herein comprises an initial administration of a first dose of an anti-CD20 antibody, and one or more subsequent administrations of a second dose of an anti-CD20 antibody, wherein the second dose is higher than the first dose. In one aspect, the administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, comprises an initial administration of a first dose of an anti-CD20 antibody, and one or more subsequent administrations of a second dose of an anti-CD20 antibody, wherein the first dose is not lower than the second dose.
[0387] In one aspect, the administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, in a treatment regimen according to the present invention is the first administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to CD19 to a subject (at least within the same course of treatment). In one aspect, no anti-CD20 antibody is administered to the subject before the administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP. In another aspect, an anti-CD20 antibody is administered before the administration of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP.
[0388] In another aspect, a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, is provided for use in combination with an anti-CD20 antibody, wherein pretreatment with a type II anti-CD20 antibody, preferably utuzumab, is performed prior to the combined treatment, wherein the time period between pretreatment and combined treatment is sufficient to reduce B cells in the individual in response to the type II anti-CD20 antibody, preferably utuzumab.
[0389] Activation of T cells can lead to severe cytokine release syndrome (CRS). In a Phase 1 study conducted by TeGenero (Suntharalingam et al., N Engl J Med (2006) 355, 1018-1028), all 6 healthy volunteers rapidly experienced near-lethal, severe cytokine release syndrome (CRS) after infusion of an inappropriate dose of a T cell stimulating, hyperagonistic anti-CD28 monoclonal antibody. Cytokine release associated with administering a T cell activating therapeutic agent to a subject, such as a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, can be significantly reduced by pre-treating the subject with a type II anti-CD20 antibody, such as obinutuzumab. The use of pretreatment (Gpt) should help to rapidly deplete B cells in both peripheral blood and secondary lymphoid organs, so that the risk of highly relevant adverse events (AEs) (e.g., CRS) from strong systemic T cell activation caused by T cell activating therapeutics is reduced, while supporting T cell activating therapeutics with exposure levels high enough to mediate tumor cell elimination from the beginning of dosing. To date, the safety profile of obinutuzumab (including cytokine release) has been evaluated and managed in hundreds of patients in ongoing clinical trials of obinutuzumab. Finally, in addition to supporting the safety profile of 4-1BB agonists provided herein that include at least one antigen binding domain that can specifically bind to tumor-associated antigens, particularly CD19 or FAP, Gpt should also help prevent the formation of anti-drug antibodies (ADA) against these unique molecules.
[0390] In the present invention, a combination of a 4-1BB agonist and an anti-CD20 antibody comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, can be used in combination with one or more other agents in therapy. For example, at least one additional therapeutic agent can be co-administered. In some aspects, the additional therapeutic agent is an immunotherapeutic agent.
[0391] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same formulation or in separate formulations), and separate administration (in which case administration of the therapeutic agent can occur before, simultaneously with, and / or after administration of one or more additional therapeutic agents). In one embodiment, administration of the therapeutic agent and administration of the additional therapeutic agent occur within about 1 month, or within about 1, 2, or 3 weeks, or within about 1, 2, 3, 4, 5, or 6 days of each other.
[0392] Methods of treatment and compositions
[0393] CD20 and CD19 are expressed on most B cells except stem cells and plasma cells (pan-B cell markers), and are frequently expressed on most human B cell malignancies, such as lymphomas and leukemias, except multiple myeloma (tumor-associated antigens), for example in non-Hodgkin lymphoma and acute lymphoblastic leukemia.
[0394] Bispecific molecules that recognize two cell surface proteins on different cell populations hold promise for redirecting cytotoxic immune cells to destroy pathogenic target cells.
[0395] In one aspect, a method for treating cancer or delaying cancer progression in a subject is provided, the method comprising administering to the subject an effective amount of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and an anti-CD20 antibody.
[0396] In one such aspect, the method further includes administering an effective amount of at least one additional therapeutic agent to the subject. In yet other aspects, a method for depleting B cells is provided herein, the method comprising administering an effective amount of a 4-1BB agonist and an anti-CD20 antibody provided herein comprising at least one antigen binding domain capable of specifically binding to CD19 to the subject. According to any of the above aspects, an "individual" or "subject" is preferably a person.
[0397] In some aspects, a composition comprising a 4-1BB agonist and an anti-CD20 antibody comprising at least one antigen binding domain capable of specifically binding to CD19 provided herein is provided, which is used for cancer immunotherapy. In certain aspects, a composition comprising a 4-1BB agonist and an anti-CD20 antibody comprising at least one antigen binding domain capable of specifically binding to CD19 provided herein is provided, which is used for a method for cancer immunotherapy.
[0398] In yet another aspect, provided herein is a composition comprising a 4-1BB agonist and an anti-CD20 antibody comprising at least one antigen binding domain capable of specifically binding to CD19 provided herein for use in the manufacture or preparation of a medicament. In one embodiment, the medicament is used to treat a B cell proliferative disorder. In yet another embodiment, the medicament is used to treat a B cell proliferative disorder, the method comprising administering an effective amount of the medicament to an individual having a B cell proliferative disorder. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual. In yet another embodiment, the medicament is used to deplete B cells. B cell proliferative disorders are selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin lymphoma (HL). In a specific aspect, the B cell cancer is non-Hodgkin's lymphoma or acute lymphoblastic leukemia.
[0399] In yet another aspect, a method for treating a B cell cancer is provided herein. In one embodiment, the method comprises administering an effective amount of an anti-human CD20 antibody to an individual having such a B cell cancer. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to the individual, as described below. An "individual" according to any of the above embodiments may be a human. In one embodiment, the B cell cancer is a B cell lymphoma or a B cell leukemia. In one embodiment, the B cell cancer is a non-Hodgkin lymphoma or an acute lymphoblastic leukemia.
[0400] The combination therapy noted above encompasses combined administration (where two or more therapeutic agents are included in the same formulation or in separate formulations), and separate administration, in which case administration of the antibodies reported herein can occur before, simultaneously with, and / or after administration of one or more additional therapeutic agents. In one embodiment, administration of the anti-human CD20 antibody and administration of the additional therapeutic agent occur within about 1 month, or within about 1, 2 or 3 weeks, or within about 1, 2, 3, 4, 5, or 6 days of each other.
[0401] The 4-1BB agonist and anti-CD20 antibody (and any other therapeutic agent) reported herein comprising at least one antigen binding domain capable of specifically binding CD19 can be administered by any suitable means (including parenteral, intrapulmonary, and intranasal, and if desired for local treatment, intralesional administration). Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Depending in part on whether the administration is short-lived or long-term, dosing can be performed by any suitable route (e.g., by injection, such as intravenous or subcutaneous injection). Various dosing schedules are covered herein, including but not limited to single administration or multiple administrations at multiple time points, push administration, and pulse infusion.
[0402] The 4-1BB agonists and anti-CD20 antibodies reported herein, which contain at least one antigen binding domain capable of specifically binding to CD19, will be formulated, dosed, and administered in a manner consistent with good medical practice. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the site of drug delivery, the method of administration, the schedule of administration, and other factors known to medical practitioners. The antibody is not required but is optionally formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of antibodies present in the formulation, the type of condition or treatment, and other factors discussed above. These are generally used in the same dosage and route of administration as described herein, or in about 1-99% of the dosage described herein, or in any dosage and any route determined to be appropriate empirically / clinically.
[0403] Other medications and treatments
[0404] The antigen binding molecules of the present invention can be administered in combination with one or more other agents in therapy. For example, the fusion protein of the present invention can be co-administered with at least one additional therapeutic agent. The term "therapeutic agent" encompasses any agent that can be administered for the treatment of symptoms or diseases in an individual in need of such treatment. Such additional therapeutic agents may include any active ingredients suitable for the specific indication being treated, preferably those with complementary activities that do not adversely affect each other. In certain embodiments, the additional therapeutic agent is another anticancer agent.
[0405] Such other agents are appropriately combined in an amount effective for the intended purpose. The effective amount of such other agents depends on the amount of the fusion protein used, the type of illness or treatment, and other factors discussed above. Antigen binding molecules are generally used in the same dosage and administration route as described herein, or about 1 to 99% of the dosage described herein, or in any dosage and any route determined to be appropriate empirically / clinically.
[0406] Such combination therapies mentioned above encompass both combined administration (wherein two or more therapeutic agents are included in the same composition or in separate compositions) and separate administration, in which case administration of the antigen binding molecules of the present invention may occur before, simultaneously with, and / or after administration of the additional therapeutic agents and / or adjuvants.
[0407] Products (Kits)
[0408] In another aspect of the invention, a kit is provided, which contains materials useful for treating, preventing and / or diagnosing the conditions described above. The kit comprises at least one container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed from a variety of materials such as glass or plastic. The container contains a composition that is effective for treating, preventing and / or diagnosing the condition by itself or in combination with another composition and may have a sterile access port (for example, the container may be a vial or intravenous solution bag with a stopper pierceable by a hypodermic injection needle). At least two active agents in the kit are an anti-CD20 antibody of the present invention and a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP.
[0409] In one specific aspect, provided is a kit for treating cancer or delaying cancer progression in a subject, comprising a package comprising (A) a first composition comprising, as an active ingredient, a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a pharmaceutically acceptable excipient; (B) a second composition comprising, as an active ingredient, an anti-CD20 antibody and a pharmaceutically acceptable excipient; and (C) instructions for use of the composition in combination therapy.
[0410] The label or package insert indicates how the composition is used to treat the selected condition and provides instructions for using the composition in combination therapy. In addition, the kit may include (a) a first container containing a composition, wherein the composition comprises a 4-1BB agonist of the present invention comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP; and (b) a second container containing a composition, wherein the composition comprises an anti-CD20 antibody. In addition, the kit may include one or more additional containers containing additional active components that can be used in combination. The article of manufacture in this embodiment of the invention may further include a package insert indicating that the composition can be used to treat a specific condition.
[0411] Alternatively or additionally, the kit may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0412] Table D (sequence)
[0413]
[0414]
[0415]
[0416]
[0417]
[0418]
[0419]
[0420]
[0421]
[0422]
[0423]
[0424]
[0425]
[0426]
[0427]
[0428] General information about the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). The amino acids of the antibody chains are numbered and referred to according to the numbering system according to Kabat as defined above (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)).
[0429] Aspects of the Invention
[0430] In the following, some aspects of the present invention are listed.
[0431] 1. A 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the 4-1BB agonist comprises at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP.
[0432] 2. The 4-1BB agonist for use in the method of aspect 1, wherein the 4-1BB agonist and the anti-CD20 antibody are administered concomitantly.
[0433] 3. The 4-1BB agonist for use in the method of aspect 1 or 2, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
[0434] 4. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is administered concurrently with the anti-CD20 antibody, before the anti-CD20 antibody, or after the anti-CD20 antibody.
[0435] 5. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.
[0436] 6. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
[0437] 7. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and an antigen binding domain capable of specifically binding to CD19.
[0438] 8. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19 is not internalized by CD19-expressing B cells.
[0439] 9. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one module capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V H CD19), comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain variable region (V LCD19), which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a VH domain, which comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL domain, which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0440] 10. The 4-1BB agonist for use in the method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V L ... H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0441] 11. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.
[0442] 12. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.
[0443] 13. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce or eliminate binding to an Fc receptor and / or effector function.
[0444] 14. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0445] 15. The 4-1BB agonist for use in the method of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0446] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0447] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0448] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0449] 16. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0450] (a) at least one Fab domain capable of specifically binding to CD19, and
[0451] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0452] wherein the antigen binding molecule is characterized by
[0453] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0454] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0455] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof connected to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof connected to the VL or VH of said polypeptide via a peptide linker.
[0456] 17. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0457] (a) at least one Fab domain capable of specifically binding to CD19, comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19), and
[0458] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0459] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0460] 18. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0461] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0462] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0463] c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:39, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:40;
[0464] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:33, a first light chain comprising the amino acid sequence of SEQ ID NO:34, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41, and a second light chain comprising the amino acid sequence of SEQ ID NO:42;
[0465] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0466] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0467] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0468] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0469] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 48, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 49, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 50;
[0470] j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 47, a first light chain comprising the amino acid sequence of SEQ ID NO: 48, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0471] k) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and
[0472] l) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:48, a first heavy chain comprising the amino acid sequence of SEQ ID NO:51 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:52.
[0473] 19. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0474] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0475] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0476] 20. A 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0477] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0478] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker, and
[0479] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.
[0480] 21. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0481] (a) A molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53,
[0482] (b) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19) and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53;
[0483] (c) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 54, and
[0484] (d) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO:55.
[0485] 22. The 4-1BB agonist for use in the method according to any one of aspects 1 to 3 above, wherein the 4-1BB agonist is an anti-CD19 / anti-4-1BB bispecific antibody.
[0486] 23. The 4-1BB agonist for use in a method according to any one of aspects 1 to 14, wherein the anti-CD20 antibody is a type I anti-CD20 antibody.
[0487] 24. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the anti-CD20 antibody is rituximab.
[0488] 25. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the anti-CD20 antibody is a type II anti-CD20 antibody.
[0489] 26. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the anti-CD20 antibody is an afucosylated anti-CD20 antibody.
[0490] 27. The 4-1BB agonist for use in a method according to any one of the preceding aspects 1 to 14 or 17 or 18, wherein the anti-CD20 antibody is obinutuzumab.
[0491] 28. The 4-1BB agonist for use in a method according to any one of the preceding aspects 1 to 14, wherein the anti-CD20 antibody is rituximab or obinutuzumab.
[0492] 29. The 4-1BB agonist for use in the method of any of the preceding aspects, wherein the anti-CD20 antibody comprises a heavy chain variable region (V H ) comprising a CDR-H1 sequence of SEQ ID NO: 73, a CDR-H2 sequence of SEQ ID NO: 74, and a CDR-H3 sequence of SEQ ID NO: 75. H CD20), and / or a light chain variable region (V L L1 sequence comprising SEQ ID NO: 76, a CDR-L2 sequence of SEQ ID NO: 77, and a CDR-L3 sequence of SEQ ID NO: 78 L CD20).
[0493] 30. The 4-1BB agonist for use in the method of any one of the preceding aspects, wherein the second antigen binding domain comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 79. H CD20) and / or a light chain variable region (V LCD20) comprising the amino acid sequence of SEQ ID NO: 80 L CD20).
[0494] 31. A 4-1BB agonist for use in a method according to any of the preceding aspects, wherein the 4-1BB agonist comprises an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.
[0495] 32. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist comprises an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0496] 33. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the combination is administered at intervals of about one to three weeks.
[0497] 34. A pharmaceutical product comprising (A) a first composition comprising as an active ingredient a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and a pharmaceutically acceptable excipient; and (B) a second composition comprising as an active ingredient an anti-CD20 antibody and a pharmaceutically acceptable excipient, for use in combination, sequentially or simultaneously, in the treatment of a disease, particularly cancer.
[0498] 35. The pharmaceutical product of aspect 34, for use in the treatment of B-cell proliferative disorders, in particular a disease selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin lymphoma (HL).
[0499] 36. A pharmaceutical composition comprising a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and an anti-CD20 antibody.
[0500] 37. The pharmaceutical composition of aspect 36, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, in particular CD19 or FAP, and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
[0501] 38. The pharmaceutical composition of aspect 36 or 37, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, is administered concurrently with, before, or after the anti-CD20 antibody.
[0502] 39. The pharmaceutical composition of any one of aspects 36 to 38, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.
[0503] 40. The pharmaceutical composition of any one of aspects 36 to 39, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
[0504] 41. The pharmaceutical composition of any one of aspects 36 to 40, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, in particular CD19.
[0505] 42. The pharmaceutical composition of any one of aspects 36 to 41, wherein the 4-1BB agonist is not internalized by B cells.
[0506] 43. The pharmaceutical composition of any one of aspects 36 to 42, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one module capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V H CD19), comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain variable region (V L CD19), which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a VH domain, which comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL domain, which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0507] 44. The pharmaceutical composition of any one of aspects 36 to 43, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V L ... H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0508] 45. The pharmaceutical composition of any one of aspects 36 to 44, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.
[0509] 46. The pharmaceutical composition of any one of aspects 36 to 44, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain.
[0510] 47. The pharmaceutical composition of any one of aspects 36 to 46, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.
[0511] 48. The pharmaceutical composition of any one of aspects 36 to 47, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0512] 49. The pharmaceutical composition of any one of aspects 36 to 48, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0513] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0514] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0515] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0516] 50. The pharmaceutical composition of any one of aspects 36 to 49, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0517] (a) at least one Fab domain capable of specifically binding to CD19, and
[0518] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0519] wherein the antigen binding molecule is characterized by
[0520] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0521] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0522] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof connected to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof connected to the VL or VH of said polypeptide via a peptide linker.
[0523] 51. The pharmaceutical composition of any one of aspects 36 to 50, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0524] (a) at least one Fab domain capable of specifically binding to CD19, comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V HCD19) and a light chain variable region (V L ... L CD19), and
[0525] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0526] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0527] 52. The pharmaceutical composition of any one of aspects 36 to 51, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0528] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0529] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0530] c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:39, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:40;
[0531] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:33, a first light chain comprising the amino acid sequence of SEQ ID NO:34, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41, and a second light chain comprising the amino acid sequence of SEQ ID NO:42;
[0532] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0533] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0534] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0535] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0536] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 48, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 49, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 50;
[0537] j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 47, a first light chain comprising the amino acid sequence of SEQ ID NO: 48, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0538] k) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and
[0539] l) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:48, a first heavy chain comprising the amino acid sequence of SEQ ID NO:51 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:52.
[0540] 53. The pharmaceutical composition of any one of aspects 36 to 48, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0541] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0542] (b) A polypeptide comprising 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker.
[0543] 54. The pharmaceutical composition of any one of aspects 36 to 48 or 53, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0544] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0545] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker, and
[0546] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.
[0547] 55. The pharmaceutical composition of any one of aspects 36 to 48 or 53 or 54, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0548] (a) A molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53,
[0549] (b) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19) and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53;
[0550] (c) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 54, and
[0551] (d) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO:55.
[0552] 56. The pharmaceutical composition of any one of aspects 36 to 38, wherein the 4-1BB agonist is an anti-CD19 / anti-4-1BB bispecific antibody.
[0553] 57. The pharmaceutical composition of any one of aspects 36 to 56, wherein the anti-CD20 antibody comprises a heavy chain variable region (V H ) comprising a CDR-H1 sequence of SEQ ID NO: 73, a CDR-H2 sequence of SEQ ID NO: 74, and a CDR-H3 sequence of SEQ ID NO: 75. H CD20), and / or a light chain variable region (V L L1 sequence comprising SEQ ID NO: 76, a CDR-L2 sequence of SEQ ID NO: 77, and a CDR-L3 sequence of SEQ ID NO: 78 L CD20).
[0554] 58. The pharmaceutical composition of any one of aspects 36 to 57, wherein the anti-CD20 antibody comprises a heavy chain variable region (V H CD20) and / or a light chain variable region (V LCD20) comprising the amino acid sequence of SEQ ID NO: 80 L CD20).
[0555] 59. The pharmaceutical composition of any one of aspects 36 to 58, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 is used in combination with an anti-CD20 antibody and wherein the combination is administered at intervals of about one to three weeks.
[0556] 60. The pharmaceutical composition according to any one of aspects 36 to 59, for use in treating a proliferative disease, particularly cancer, or in delaying the progression of a proliferative disease, particularly cancer.
[0557] 61. The pharmaceutical composition of any one of aspects 36 to 60, for use in the treatment of a B-cell proliferative disorder, in particular a disease selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin lymphoma (HL).
[0558] 62. A kit for treating cancer or delaying cancer progression in a subject, comprising a package comprising (A) a first composition comprising as an active component a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and a pharmaceutically acceptable excipient; (B) a second composition comprising as an active component an anti-CD20 antibody and a pharmaceutically acceptable excipient; and (C) instructions for use of the composition in combination therapy.
[0559] 63. Use of a combination of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and an anti-CD20 antibody in the manufacture of a medicament for treating a proliferative disease, particularly cancer, or delaying the progression of a proliferative disease, particularly cancer.
[0560] 64. Use of a combination of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and an anti-CD20 antibody in the manufacture of a medicament, wherein the medicament is used to treat a B-cell proliferative disorder, particularly a disease selected from the group consisting of non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM) and Hodgkin's lymphoma (HL).
[0561] 65. A method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen, particularly CD19 or FAP, and an anti-CD20 antibody.
[0562] 66. A method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule.
[0563] 67. The method of aspect 65 or 66, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain.
[0564] 68. The method of any one of aspects 65 to 67, wherein the 4-1BB agonist is an antigen binding molecule comprising a modified Fc domain that reduces Fcγ receptor binding and / or effector function.
[0565] 69. The method of any one of aspects 65 to 68, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof.
[0566] 70. The method of any one of aspects 65 to 69, wherein the -1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and an antigen binding domain capable of specifically binding to CD19.
[0567] 71. The method of any one of aspects 65 to 70, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
[0568] 72. The method of any one of aspects 65 to 71, wherein the 4-1BB agonist is not internalized in B cells.
[0569] 73. The method of any one of aspects 65 to 72, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one module capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V H CD19), comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain variable region (V LCD19), which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a VH domain, which comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, and a VL domain, which comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0570] 74. The method of any one of aspects 65 to 73, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to CD19, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V L ... H CD19) and a light chain variable region (V L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0571] 75. The method of any one of aspects 65 to 74, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain composed of a first and a second subunit capable of stably associating.
[0572] 76. The method of any one of aspects 65 to 75, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.
[0573] 77. The method of any one of aspects 65 to 76, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.
[0574] 78. The method of any one of aspects 65 to 77, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.
[0575] 79. The method of any one of aspects 65 to 78, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0576] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0577] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0578] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0579] 80. The method of any one of aspects 65 to 79, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0580] (a) at least one Fab domain capable of specifically binding to CD19, and
[0581] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0582] wherein the antigen binding molecule is characterized by
[0583] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or
[0584] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or
[0585] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof connected to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof connected to the VL or VH of said polypeptide via a peptide linker.
[0586] 81. The method of any one of aspects 65 to 80, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0587] (a) at least one Fab domain capable of specifically binding to CD19, comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19), and
[0588] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0589] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0590] 82. The method of any one of aspects 65 to 81, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0591] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0592] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the amino acid sequence of SEQ ID NO: 38;
[0593] c) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:39, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:40;
[0594] d) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:33, a first light chain comprising the amino acid sequence of SEQ ID NO:34, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41, and a second light chain comprising the amino acid sequence of SEQ ID NO:42;
[0595] e) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44;
[0596] f) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:34, a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:46;
[0597] g) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:35, and a second light chain comprising the amino acid sequence of SEQ ID NO:36;
[0598] h) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:37, and a second light chain comprising the amino acid sequence of SEQ ID NO:38;
[0599] i) a molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO: 48, a first heavy chain comprising the amino acid sequence of SEQ ID NO: 49, and a second heavy chain comprising the amino acid sequence of SEQ ID NO: 50;
[0600] j) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 47, a first light chain comprising the amino acid sequence of SEQ ID NO: 48, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a second light chain comprising the amino acid sequence of SEQ ID NO: 42;
[0601] k) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and
[0602] l) A molecule comprising two light chains comprising the amino acid sequence of SEQ ID NO:48, a first heavy chain comprising the amino acid sequence of SEQ ID NO:51 and a second heavy chain comprising the amino acid sequence of SEQ ID NO:52.
[0603] 83. The method of any one of aspects 65 to 82, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0604] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0605] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.
[0606] 84. The method of any one of aspects 65 to 83, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0607] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0608] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker, and
[0609] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.
[0610] 85. The method of any one of aspects 65 to 84, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0611] (a) A molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53,
[0612] (b) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19) and a fusion protein comprising the amino acid sequence of SEQ ID NO: 53;
[0613] (c) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO: 54, and
[0614] (d) a molecule comprising a heavy chain variable region (V H CD19), a light chain variable region (V L CD19), and a fusion protein comprising the amino acid sequence of SEQ ID NO:55.
[0615] 86. The method of any one of aspects 65 to 68, wherein the 4-1BB agonist is an anti-CD19 / anti-4-1BB bispecific antibody.
[0616] 87. The method of any one of aspects 65 to 86, wherein the anti-CD20 antibody comprises a heavy chain variable region (V H ) comprising a CDR-H1 sequence of SEQ ID NO: 73, a CDR-H2 sequence of SEQ ID NO: 74, and a CDR-H3 sequence of SEQ ID NO: 75.H CD20), and / or a light chain variable region (V L L1 sequence comprising SEQ ID NO: 76, a CDR-L2 sequence of SEQ ID NO: 77, and a CDR-L3 sequence of SEQ ID NO: 78 L CD20).
[0617] 88. The method of any one of aspects 65 to 87, wherein the anti-CD20 antibody comprises a heavy chain variable region (V H CD20) and / or a light chain variable region (V LCD20) comprising the amino acid sequence of SEQ ID NO: 80 L CD20).
[0618] 89. The method of any one of aspects 65 to 86, wherein the anti-CD20 antibody comprises rituximab.
[0619] 90. The method of any one of aspects 65 to 89, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 is used in combination with an anti-CD20 antibody and wherein the combination is administered at intervals of about one to three weeks.
[0620] 91. The method of any one of aspects 65 to 90, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, particularly CD19 or FAP, and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
[0621] 92. The method of any one of aspects 65 to 91, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 and the anti-CD20 antibody are administered intravenously or subcutaneously.
[0622] 93. The method of any one of aspects 65 to 92, wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specifically binding to CD19 is administered concurrently with the anti-CD20 antibody, before the anti-CD20 antibody, or after the anti-CD20 antibody.
[0623] 94. A combination comprising a 4-1BB (CD137) agonist and an anti-CD20 antibody, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.
[0624] 95. The combination of aspect 94, wherein the 4-1BB agonist and the anti-CD20 antibody are administered concomitantly.
[0625] 96. The combination of aspect 94 or 95, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
[0626] 97. The combination of any one of aspects 94 to 96, wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to CD19.
[0627] 98. The combination of any one of aspects 94 to 97, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.
[0628] 99. The combination of any one of aspects 94 to 98, wherein the 4-1BB agonist comprises three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.
[0629] 100. A combination of any one of aspects 94 to 99, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL ectodomains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) a heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V H CD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L CD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V HCD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L CD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.
[0630] 101. A combination of any one of aspects 94 to 100, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL ectodomains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 21. H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19).
[0631] 102. The combination of any one of aspects 94 to 101, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.
[0632] 103. The combination of any one of aspects 94 to 102, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0633] (a) at least one antigen binding domain capable of specifically binding to CD19,
[0634] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0635] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.
[0636] 104. The combination of any one of aspects 94 to 103, wherein the 4-1BB agonist is an antigen binding molecule comprising:
[0637] (a) at least one Fab domain capable of specifically binding to CD19, the Fab domain capable of specifically binding to CD19 comprising a heavy chain variable region (V H CD19) and a light chain variable region (V L) comprising the amino acid sequence of SEQ ID NO: 22 L CD19) or a heavy chain variable region (V H CD19) and a light chain variable region (V L ... L CD19), and
[0638] (b) a first and a second polypeptide linked to each other via a disulfide bond,
[0639] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
[0640] 105. The combination of any one of aspects 94 to 104, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:
[0641] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 35, and a second light chain comprising the amino acid sequence of SEQ ID NO: 36;
[0642] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 33, a first light chain comprising the amino acid sequence of SEQ ID NO: 34, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 37, and a second light chain comprising the...
Claims
1. A 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody and wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.
2. The 4-1BB agonist for use in the method of claim 1, wherein the 4-1BB agonist and the anti-CD20 antibody are administered concomitantly.
3. The 4-1BB agonist for use in the method of claim 1 or 2, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition or separately in two or more different compositions.
4. The 4-1BB agonist for use in the method of any one of claims 1 to 3, wherein the 4-1BB agonist comprises at least one antigen binding domain capable of specifically binding to CD19.
5. The 4-1BB agonist for use in the method of any one of claims 1 to 4, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.
6. The 4-1BB agonist for use in the method according to any one of claims 1 to 5, wherein the 4-1BB agonist comprises three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:
5.
7. The 4-1BB agonist for use in the method of any one of claims 1 to 6, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL ectodomains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises (a) Heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V H CD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L CD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) Heavy chain variable region (V H CD19 and light chain variable region (V L CD19), the heavy chain variable region (V H CD19) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L CD19) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
20.
8. The 4-1BB agonist for use in the method of any one of claims 1 to 7, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to CD19 and three 4-1BBL external domains or fragments thereof, wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V L ... H CD19) and a light chain variable region (V L CD19) or wherein the antigen binding domain capable of specifically binding to CD19 comprises a heavy chain variable region (V H CD19) and a light chain variable region (V L CD19).
9. The 4-1BB agonist for use in the method according to any one of claims 1 to 8, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.
10. The 4-1BB agonist for use in the method of any one of claims 1 to 9, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce or eliminate binding to an Fc receptor and / or effector function.
